<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>

<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31584490</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-0229</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>44</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical nuclear medicine</Title>
                <ISOAbbreviation>Clin Nucl Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e597-e601</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/RLU.0000000000002791</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">In this study, we investigated the relationship of cerebral tau deposition (F-tau-AD-ML 104 PET/CT) with glucose metabolism (F-FDG PET/CT) and cognitive function in patients with Alzheimer disease (AD).</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Seventy subjects (Mini Mental State Examination [MMSE] score &lt;18 = 37 [AD]; MMSE score, 18-24 = 16 [early AD]) and 17 controls were included in this study. All participants underwent detailed neurological and neuropsychological evaluation, followed by F-tau-AD-ML 104 and F-FDG PET/CT imaging. Region-wise SUVmax ratios at 50 to 60 minutes postinjection were calculated for F-tau-AD-ML 104 and F-FDG, using the cerebellar cortex as the reference region. Linear models were used to investigate the association of regional F-tau-AD-ML 104 retention with F-FDG uptake and cognition (MMSE scores).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">F-Tau-AD-ML 104 retention was observed in the parietal lobe, temporal lobe, hippocampus, parahippocampus, frontal lobe, anterior and posterior cingulate, and precuneus in advanced and early AD patient as compared with normal controls with regional hypometabolism in overlapping regions on F-FDG PET. Significant negative association was found between F-tau-AD-ML 104 regional retention and glucose metabolism in the parietal lobe, temporal lobe, hippocampus, parahippocampus, frontal lobe, anterior and posterior cingulate, and precuneus among patients with advanced and early AD. In advanced and early AD patients, a negative association was found between F-tau-AD-ML 104 regional retention (precuneus) and cognition (MMSE score), whereas a positive association was observed between F-FDG regional uptake (precuneus) and cognition (MMSE score).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tau pathology overlapped with areas of hypometabolism on FDG PET in the brains of AD patients. Tau deposition was found to have negative association with cognitive scores in these patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Baghel</LastName>
                    <ForeName>Vivek</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tripathi</LastName>
                    <ForeName>Madhavi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parida</LastName>
                    <ForeName>Girish</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gupta</LastName>
                    <ForeName>Ravikant</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yadav</LastName>
                    <ForeName>Saroj</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Geriatrics, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumar</LastName>
                    <ForeName>Praveen</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dey</LastName>
                    <ForeName>A B</ForeName>
                    <Initials>AB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Geriatrics, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Damle</LastName>
                    <ForeName>Nishikant Avinash</ForeName>
                    <Initials>NA</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumar</LastName>
                    <ForeName>Rajeev</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Geriatrics, All India Institute of Medical Sciences, New Delhi, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bal</LastName>
                    <ForeName>Chandrasekhar</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Departments of Nuclear Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Nucl Med</MedlineTA>
            <NlmUniqueID>7611109</NlmUniqueID>
            <ISSNLinking>0363-9762</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0Z5B2CJX4D</RegistryNumber>
                <NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>IY9XDZ35W2</RegistryNumber>
                <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31584490</ArticleId>
            <ArticleId IdType="doi">10.1097/RLU.0000000000002791</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31542965</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4563</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>74</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>11</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hypertension (Dallas, Tex. : 1979)</Title>
                <ISOAbbreviation>Hypertension</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Blood Pressure Variability and Progression of Clinical Alzheimer Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1172-1180</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1161/HYPERTENSIONAHA.119.13664</ELocationID>
            <Abstract>
                <AbstractText>Blood pressure variability (BPV) has been shown to have predictive value over blood pressure (BP) levels alone in stroke patients. We assessed whether BPV predicts cognitive and functional decline in Alzheimer disease, using data from a randomized trial (NILVAD [A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease]). Patients with mild-to-moderate Alzheimer disease were included if they had ≥3 office BP measurements available to determine visit-to-visit BPV. Day-to-day BPV was assessed using home BP measurements in a subsample. The variation independent of mean was used to calculate BPV. Outcomes were change in Alzheimer's Disease Assessment Scale-cognitive subscale-12 and Disability Assessment for Dementia after 1 and 1.5 years. A total of 460 patients aged 72.1 (SD=8.1) years, with mean BP of 134.0/75.1 (10.9/6.3) mm Hg were included. After 1 year, patients in the highest quartile of BPV had deteriorated more on Alzheimer's Disease Assessment Scale-cognitive subscale compared with patients in the lowest quartile (systolic: β, 2.24 [95% CI, 0.11-4.38], <i>P</i>=0.040; diastolic: β, 2.54 [95% CI, 0.33-4.75] <i>P</i>=0.024). This association was still present after 1.5 years (systolic: β, 2.86 [95% CI, 0.35-5.36], <i>P</i>=0.026; diastolic: β, 3.30 [95% CI, 0.67-5.93], <i>P</i>=0.014). There was no effect of visit-to-visit BPV on Disability Assessment for Dementia. Day-to-day BPV was available for 46 patients. Significant associations were observed between day-to-day BPV and deterioration on Alzheimer's Disease Assessment Scale-cognitive subscale (systolic: <i>P</i>=0.036) and Disability Assessment for Dementia (systolic: <i>P</i>=0.020; diastolic: <i>P</i>=0.007) after 1 year, but not after 1.5 years. All associations were adjusted for potential confounders, including intervention group. In conclusion, this post hoc analysis indicates that higher visit-to-visit and day-to-day BPV might be associated with progression of Alzheimer disease. Targeting BPV may be a future target to slow decline in patients with Alzheimer disease. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT02017340.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>de Heus</LastName>
                    <ForeName>Rianne A A</ForeName>
                    <Initials>RAA</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Geriatric Medicine, Radboud umc University Medical Center, Radboudumc Alzheimer Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands (R.A.A.d.H., M.G.M.O.R., J.A.H.R.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olde Rikkert</LastName>
                    <ForeName>Marcel G M</ForeName>
                    <Initials>MGM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Geriatric Medicine, Radboud umc University Medical Center, Radboudumc Alzheimer Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands (R.A.A.d.H., M.G.M.O.R., J.A.H.R.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tully</LastName>
                    <ForeName>Phillip J</ForeName>
                    <Initials>PJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Medicine, The University of Adelaide, Australia (P.J.T.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawlor</LastName>
                    <ForeName>Brian A</ForeName>
                    <Initials>BA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mercer's Institute for Research on Ageing, St. James's Hospital, Dublin, Ireland (B.A.L.).</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Gerontology, Trinity College Institute of Neuroscience, Dublin, Ireland (B.A.L.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Claassen</LastName>
                    <ForeName>Jurgen A H R</ForeName>
                    <Initials>JAHR</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Geriatric Medicine, Radboud umc University Medical Center, Radboudumc Alzheimer Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands (R.A.A.d.H., M.G.M.O.R., J.A.H.R.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>NILVAD Study Group</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02017340</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hypertension</MedlineTA>
            <NlmUniqueID>7906255</NlmUniqueID>
            <ISSNLinking>0194-911X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0214FUT37J</RegistryNumber>
                <NameOfSubstance UI="C035100">nilvadipine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I9ZF7L6G2L</RegistryNumber>
                <NameOfSubstance UI="D009543">Nifedipine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009543" MajorTopicYN="N">Nifedipine</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Alzheimer disease</Keyword>
            <Keyword MajorTopicYN="Y">activities of daily living</Keyword>
            <Keyword MajorTopicYN="Y">blood pressure</Keyword>
            <Keyword MajorTopicYN="Y">cognition</Keyword>
            <Keyword MajorTopicYN="Y">hypertension</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31542965</ArticleId>
            <ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.13664</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31476904</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4563</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>74</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>10</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hypertension (Dallas, Tex. : 1979)</Title>
                <ISOAbbreviation>Hypertension</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Combinatorial Treatment Using Umbilical Cord Perivascular Cells and Aβ Clearance Rescues Vascular Function Following Transient Hypertension in a Rat Model of Alzheimer Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1041-1051</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1161/HYPERTENSIONAHA.119.13187</ELocationID>
            <Abstract>
                <AbstractText>Transient hypertension is a risk factor for Alzheimer disease (AD), but the effects of this interaction on brain vasculature are understudied. Addressing vascular pathology is a promising avenue to potentiate the efficacy of treatments for AD. We used arterial spin labeling magnetic resonance imaging to longitudinally assess brain vascular function and immunohistopathology to examine cerebrovascular remodeling and amyloid load. Hypertension was induced for 1 month by administration of l-N<sup>G</sup>-nitroarginine-methyl-ester in TgF344-AD rats at the prodromal stage. Following hypertension, nontransgenic rats showed transient cerebrovascular changes, whereas TgF344-AD animals exhibited sustained alterations in cerebrovascular function. Human umbilical cord perivascular cells in combination with scyllo-inositol, an inhibitor of Aβ oligomerization, resulted in normalization of hippocampal vascular function and remodeling, in contrast to either treatment alone. Prodromal stage hypertension exacerbates latter AD pathology, and the combination of human umbilical cord perivascular cells with amyloid clearance promotes cerebrovascular functional recovery.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bazzigaluppi</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beckett</LastName>
                    <ForeName>Tina L</ForeName>
                    <Initials>TL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koletar</LastName>
                    <ForeName>Margaret M</ForeName>
                    <Initials>MM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hill</LastName>
                    <ForeName>Mary E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lai</LastName>
                    <ForeName>Aaron</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trivedi</LastName>
                    <ForeName>Arunachala</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thomason</LastName>
                    <ForeName>Lynsie</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dorr</LastName>
                    <ForeName>Adrienne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gallagher</LastName>
                    <ForeName>Denis</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>CReATe Research Program, Toronto, Canada (D.G., C.L.L.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Librach</LastName>
                    <ForeName>Clifford L</ForeName>
                    <Initials>CL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Division of Obstetrics and Gynaecology, Laboratory Medicine and Pathobiology (C.L.), University of Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>CReATe Research Program, Toronto, Canada (D.G., C.L.L.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joo</LastName>
                    <ForeName>Illsung L</ForeName>
                    <Initials>IL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McLaurin</LastName>
                    <ForeName>JoAnne</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stefanovic</LastName>
                    <ForeName>Bojana</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Sunnybrook Research Institute, Toronto, Canada (P.B., T.L.B., M.M.K., M.E.H., A.L., A.T., L.T., A.D., C.L.L., I.L.J., J.M., B.S.).</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Biophysics (B.S.), University of Toronto, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 AG057665</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>09</Month>
                <Day>03</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hypertension</MedlineTA>
            <NlmUniqueID>7906255</NlmUniqueID>
            <ISSNLinking>0194-911X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013113">Spin Labels</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013113" MajorTopicYN="N">Spin Labels</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Alzheimer disease</Keyword>
            <Keyword MajorTopicYN="Y">hypertension</Keyword>
            <Keyword MajorTopicYN="Y">inositol</Keyword>
            <Keyword MajorTopicYN="Y">risk factor</Keyword>
            <Keyword MajorTopicYN="Y">umbilical cord</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31476904</ArticleId>
            <ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.13187</ArticleId>
            <ArticleId IdType="pmc">PMC6739147</ArticleId>
            <ArticleId IdType="mid">NIHMS1536946</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31464906</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>23</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>35</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Vitamin D concentration and risk of Alzheimer disease: A meta-analysis of prospective cohort studies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e16804</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000016804</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Considerable controversy exists on the association between serum vitamin D concentrations and Alzheimer disease (AD) risk. This study aimed to synthesize the association of serum vitamin D concentrations with AD in adults.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Embase, and Cochrane library databases were searched for prospective cohort studies with data on serum vitamin D concentrations and AD risk.</AbstractText>
                <AbstractText Label="RESULT" NlmCategory="RESULTS">The studies that reported the adjusted relative risks (RRs) with 95% confidence intervals (CIs) of AD associated with serum vitamin D concentrations were included and subjected to subgroup analyses. Six prospective cohort studies with 1607 AD cases and 21,692 individuals were included in the meta-analysis. In 4 cohort studies with information about serum vitamin D concentrations &lt;25 and 25 to 50 nmol/L, the random effects summary estimate did not show an increased risk of AD after adjustment for the established risk factors, while 3 cohort studies reported the RRs for incident AD per standard deviation (SD) decrease in serum vitamin D concentration and the random effects summary estimate did not show an increased risk of AD after adjustment for the established risk factors.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The current meta-analysis indicated that serum vitamin D deficiency (&lt;25 nmol/L) or insufficiency (25-50 nmol/L) was not statistically significant and associated with the risk of AD.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Kui</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaoguang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurology Department, Peking Union Medical College Hospital, Beijing.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Yongning</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gastroenterology Department, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>1406-16-2</RegistryNumber>
                <NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014808" MajorTopicYN="N">Vitamin D Deficiency</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31464906</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000016804</ArticleId>
            <ArticleId IdType="pii">00005792-201908300-00018</ArticleId>
            <ArticleId IdType="pmc">PMC6736453</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Neuropsychobiology. 2010 Aug;62(3):139-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20628264</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>World Health Organ Tech Rep Ser. 2003;921:1-164, back cover</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15293701</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Aspects Med. 2008 Dec;29(6):415-22</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18579197</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Hypertension. 2005 Jul;46(1):200-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15911742</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Dement. 2017 Nov;13(11):1207-1216</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28522216</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Stat Med. 2002 Jun 15;21(11):1539-58</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12111919</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neurology. 2012 Sep 25;79(13):1397-405</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23008220</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 2011 Jan;96(1):53-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21118827</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neurobiol Dis. 2015 Dec;84:84-98</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26160191</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Dialogues Clin Neurosci. 2009;11(2):111-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19585947</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Nutr Soc. 2018 May;77(2):124-134</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29233204</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Epidemiol. 2010 Sep;25(9):603-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20652370</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Endocrinology. 1986 Apr;118(4):1433-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">3753932</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biometrics. 1994 Dec;50(4):1088-101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7786990</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21646368</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S265-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19545951</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biometrics. 2000 Jun;56(2):455-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10877304</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2016;51(2):451-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26890771</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neurology. 2002 Jan 22;58(2):209-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11805246</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Arch Med Res. 2012 Nov;43(8):600-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23159715</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Maturitas. 2011 May;69(1):27-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21429678</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>N Engl J Med. 2010 Jan 28;362(4):329-44</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20107219</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nutr Neurosci. 2019 Nov;22(11):750-759</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29447107</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nutr J. 2015 Aug 01;14:76</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26231781</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nutr Bull. 2014 Dec;39(4):322-350</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25635171</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neurology. 2014 Sep 2;83(10):920-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25098535</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2017;60(3):989-997</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28984598</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neurology. 1997 Dec;49(6):1498-504</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9409336</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Trends Endocrinol Metab. 2002 Apr;13(3):100-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11893522</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Neurosci. 2001 Jan 1;21(1):98-108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11150325</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2013;33(3):659-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23042216</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMJ. 1997 Sep 13;315(7109):629-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9310563</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nutrition. 2013 Jun;29(6):828-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23415143</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Res. 2010 Oct;20(10):1352-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20736230</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Dement. 2014 May;10(3):296-302</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23871764</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA. 2000 Apr 19;283(15):2008-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10789670</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2013;37(1):147-71</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23948884</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Neurol. 2004 Mar;3(3):184-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14980533</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Neurol. 2016 Apr;15(5):455-532</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26987701</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Neurosci Res. 2003 Feb 15;71(4):575-82</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12548714</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2011;23(2):207-19</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20966550</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet. 1998 Aug 22;352(9128):609-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9746022</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Circulation. 2008 Jan 29;117(4):503-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18180395</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Clin Nutr. 2017 Apr;105(4):936-943</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28202477</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12958120</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31348306</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>30</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Evaluation of hippocampal volume and serum brain-derived neurotrophic factor as potential diagnostic markers of conversion from amnestic mild cognitive impairment to Alzheimer disease: A STROBE-compliant article.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e16604</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000016604</ELocationID>
            <Abstract>
                <AbstractText>Amnestic mild cognitive impairment (aMCI) is a transitional stage between normal aging and Alzheimer disease (AD), and is associated with an increased risk of AD. Many studies have shown that apolipoprotein E epsilon 4 (APOE ε4) genotype is a major genetic predictor of AD progression, especially in patients with aMCI. However, the application of APOE genotyping in the diagnosis of MCI progressing to AD is limited by its low sensitivity and specificity, which often leads to high false-positive rate. The aim of this study was to evaluate serum brain-derived neurotrophic factor (BDNF) and hippocampal volume as predictors of aMCI to AD transition in APOE ε4 genotype patients.A total of 178 subjects were diagnosed with aMCI. The patients with aMCI that progressed to AD within 2 years were included in the MCI-AD group (n = 86), those maintaining an aMCI diagnosis after 2 years were placed in the MCI-MCI group (n = 92), and neurologically healthy age-matched individuals were set as controls (n = 90). APOE genotypes were determined. Blood samples from all subjects were drawn at baseline, 12 months, and 24 months for serum BNDF assessments. Hippocampal delineations were monitored by magnetic resonance imaging.Compared to control group, aMCI-AD patients (the patients with aMCI that progressed to AD within 2 years) exhibited worse performance on cognitive and neuropsychological batteries. Meanwhile, we found that aMCI-AD patients were associated with abnormally low serum BDNF level and greater hippocampal volume loss than MCI-MCI patients (patients maintaining an aMCI diagnosis after 2 years). Moreover, patients with aMCI who were carriers of APOE ε4 showed a notable decrease in serum BDNF and a significant reduction in hippocampal volume, especially in those who progressed to AD.The present study demonstrates that aMCI that evolves into AD in patients with the APOE ε4 genotype may be predicted by hippocampal volume and serum BDNF.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fang</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Medical Affair Department.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Naiyi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Magnetic Resonance Imaging.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xing</LastName>
                    <ForeName>Longyan</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Magnetic Resonance Imaging.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duo</LastName>
                    <ForeName>Yali</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Laboratory, Harrison International Peace Hospital, Hengshui, Hebei, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zheng</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Central Laboratory, Harrison International Peace Hospital, Hengshui, Hebei, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C000612345">ApoE protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7171WSG8A2</RegistryNumber>
                <NameOfSubstance UI="C579455">BDNF protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName>
                <QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>7</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>7</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31348306</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000016604</ArticleId>
            <ArticleId IdType="pii">00005792-201907260-00081</ArticleId>
            <ArticleId IdType="pmc">PMC6709245</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31277107</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>07</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>27</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e16091</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000016091</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive impairment is a principal manifestation of Alzheimer disease (AD). To provide a clinical reference for the treatment of AD, a network meta-analysis (NMA) was performed to evaluate the effects of different anti-dementia drugs on the cognitive impairment exhibited by patients with AD.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Relevant randomized controlled trials are found through the Pubmed database, Web of Science, Clinical Trials, Embase, Cohranne library, Chinese National Knowledge Infrastructure database, CBM databases, and Wanfang among others. A total of 33 articles were collected, with the earliest document collected having been published in February 2017. The included reports were screened for quality of papers by using strict inclusion and exclusion criteria. All analyses were based on previously published studies reporting de-identified data; thus, no ethical approval or patient consent were required. The Mini-Mental State Examination scores informed the classification of the 33 articles into a mild subgroup, which featured 11 articles, and 12 drugs (besides a placebo); a moderate subgroup, which featured 17 articles and 15 drugs (besides a placebo); and a severe subgroup, which featured 5 articles and 3 drugs (besides a placebo).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">While donepezil, galanthamine, and huperzine demonstrated the highest efficacy in the mild cognitive dysfunction subgroup (mean difference = 5.2, 2.5, and 2.4, respectively). Donepezil, huperzine A, and rivastigmine achieved the most significant effects in the moderate cognitive dysfunction subgroup (MD = 3.8, 2.9, and 3.0 respectively). In the severe subgroup, donepezil was demonstrably superior to memantine. Donepezil was thus found to effectively address cognitive impairment in patients with AD regardless of the degrees of cognitive decline.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Evaluation of the clinically common anti-dementia drugs using NMA affirmed the utility of cholinesterase inhibitors, especially donepezil, in alleviating cognitive dysfunction of patients with AD. This study may therefore help to inform the clinical selection of pharmacotherapeutic interventions addressing cognitive dysfunction in patients with AD.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cui</LastName>
                    <ForeName>Cui-Cui</ForeName>
                    <Initials>CC</Initials>
                    <AffiliationInfo>
                        <Affiliation>China-Japan Union Hospital of Jilin University, Changchun, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xin-Yi</ForeName>
                    <Initials>XY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yuan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xing</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D000078182">Systematic Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000073216" MajorTopicYN="N">Mental Status and Dementia Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000071076" MajorTopicYN="N">Network Meta-Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>7</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>7</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>7</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31277107</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000016091</ArticleId>
            <ArticleId IdType="pii">00005792-201907050-00022</ArticleId>
            <ArticleId IdType="pmc">PMC6635177</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31232206</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">2376-1032</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>25</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of managed care &amp; specialty pharmacy</Title>
                <ISOAbbreviation>J Manag Care Spec Pharm</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The Real-World Medicare Costs of Alzheimer Disease: Considerations for Policy and Care.</ArticleTitle>
            <Pagination>
                <MedlinePgn>800-809</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.18553/jmcp.2019.25.7.800</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Headlines in popular media suggest that Alzheimer disease will bankrupt the Medicare program. Indeed, Alzheimer disease affects more than 5 million older Medicare beneficiaries.</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare total Medicare-covered (allowed) costs of patients with Alzheimer disease with the risk adjusted costs of beneficiaries without dementia over their last years of life, using claims data.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Using the Medicare 5 Percent Limited Data Set claim files from 2006-2015, we conducted a cost impact analysis of costs for up to 8 years before the year of death. Risk adjustment was performed at a beneficiary level using Medicare's 2015 Hierarchical Condition Categories. Beneficiaries were classified into dementia categories based on their diagnoses during the last 3 years of life. Costs were trend adjusted to 2015.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">This study found that 40% of deceased beneficiaries have Alzheimer disease or unspecified dementia diagnoses in their claims history. In their last 9 years of life, Alzheimer disease added about 11% to the average $17,000 per year Medicare cost for same-risk beneficiaries without dementia.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Like many diseases, Alzheimer disease and dementia are associated with aging, but unlike other diseases, families and Medicaid, rather than Medicare, bear most of the substantial cost burden. As research continues into Alzheimer treatments, it is not too early to consider how to better integrate Medicare and Medicaid to fund and improve patient outcomes, which will likely involve better diagnosis, treatment, and care coordination.</AbstractText>
                <AbstractText Label="DISCLOSURES" NlmCategory="UNASSIGNED">Funding for this project was provided by the Alliance for Aging Research, which received funding from Biogen, Eli Lilly, and Janssen Pharmaceuticals. Peschin and Jenkins are employed by the Alliance for Aging Research. Scott was employed by the Alliance for Aging Research at the time of this study and also reports consulting fees from Piramal Imaging, General Electric, and Allergan, outside of this study. Scott is chair of the Board of Directors for the Alliance for Aging Research, which is a volunteer position, and is also president of Applied Policy, a health policy and reimbursement consultancy. Pyenson and Steffens are employed by Milliman, which was contracted to work on this study. Goss Sawhney and Rotter were employed by Milliman at the time this work was performed. Milliman is a consultant to thousands of organizations in the health care industry.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pyenson</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Milliman, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sawhney</LastName>
                    <ForeName>Tia Goss</ForeName>
                    <Initials>TG</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Milliman, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Steffens</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Milliman, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rotter</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Milliman, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peschin</LastName>
                    <ForeName>Susan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>2 Alliance for Aging Research, Washington, DC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scott</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>2 Alliance for Aging Research, Washington, DC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jenkins</LastName>
                    <ForeName>Ellen</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>2 Alliance for Aging Research, Washington, DC.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Manag Care Spec Pharm</MedlineTA>
            <NlmUniqueID>101644425</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName>
                <QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31232206</ArticleId>
            <ArticleId IdType="doi">10.18553/jmcp.2019.25.7.800</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31203725</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1524-4563</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>74</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>08</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hypertension (Dallas, Tex. : 1979)</Title>
                <ISOAbbreviation>Hypertension</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>413-420</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1161/HYPERTENSIONAHA.119.12892</ELocationID>
            <Abstract>
                <AbstractText>Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 months of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 months. Mean age was 72.8±6.2 years, mean mini-mental state examination was 20.4±3.4. Nilvadipine treatment lowered systolic blood pressure (Δ=-11.5 [95% CI, -19.7 to -3.2] mm Hg; P&lt;0.01), while whole-brain gray-matter CBF remained stable (Δ=5.4 [95% CI, -6.4 to 17.2] mL/100 g per minute; P=0.36). CBF in the hippocampus increased (left: Δ=24.4 [95% CI, 4.3-44.5] mL/100 g per minute; P=0.02; right: Δ=20.1 [95% CI, -0.6 to 40.8] mL/100 g per minute; P=0.06). There was no significant change in CBF in the posterior cingulate cortex (Δ=5.2 [95% CI, -16.5 to 27.0] mL/100 g per minute; P=0.63) or other regions of interest. In conclusion, nilvadipine reduced blood pressure and increased CBF in the hippocampus, whereas other regions showed stable or small nonsignificant increases in CBF. These findings not only indicate preserved cerebral autoregulation in Alzheimer disease but also point toward beneficial cerebrovascular effects of antihypertensive treatment. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT02017340.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>de Jong</LastName>
                    <ForeName>Daan L K</ForeName>
                    <Initials>DLK</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Geriatric Medicine, Donders Institute for Brain Cognition and Behaviour (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.), Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radboudumc Alzheimer Center, Nijmegen, the Netherlands (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Heus</LastName>
                    <ForeName>Rianne A A</ForeName>
                    <Initials>RAA</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Geriatric Medicine, Donders Institute for Brain Cognition and Behaviour (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.), Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radboudumc Alzheimer Center, Nijmegen, the Netherlands (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rijpma</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Geriatric Medicine, Donders Institute for Brain Cognition and Behaviour (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.), Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radboudumc Alzheimer Center, Nijmegen, the Netherlands (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Donders</LastName>
                    <ForeName>Rogier</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Health Evidence (R.D.), Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olde Rikkert</LastName>
                    <ForeName>Marcel G M</ForeName>
                    <Initials>MGM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Geriatric Medicine, Donders Institute for Brain Cognition and Behaviour (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.), Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radboudumc Alzheimer Center, Nijmegen, the Netherlands (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Günther</LastName>
                    <ForeName>Matthias</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Frauenhofer Institute for Medical Imaging Computing MEVIS, Bremen, Germany (M.G.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawlor</LastName>
                    <ForeName>Brian A</ForeName>
                    <Initials>BA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Trinity College Institute of Neuroscience, Dublin, Ireland (B.A.L.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Osch</LastName>
                    <ForeName>Matthias J P</ForeName>
                    <Initials>MJP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden University Medical Center, the Netherlands (M.J.P.v.O.).</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Claassen</LastName>
                    <ForeName>Jurgen A H R</ForeName>
                    <Initials>JAHR</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Department of Geriatric Medicine, Donders Institute for Brain Cognition and Behaviour (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.), Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Radboudumc Alzheimer Center, Nijmegen, the Netherlands (D.L.K.d.J., R.A.A.d.H., A.R., M.G.M.O.R., J.A.H.R.C.).</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT02017340</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Hypertension</MedlineTA>
            <NlmUniqueID>7906255</NlmUniqueID>
            <ISSNLinking>0194-911X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0214FUT37J</RegistryNumber>
                <NameOfSubstance UI="C035100">nilvadipine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I9ZF7L6G2L</RegistryNumber>
                <NameOfSubstance UI="D009543">Nifedipine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009543" MajorTopicYN="N">Nifedipine</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018608" MajorTopicYN="N">Ultrasonography, Doppler</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Alzheimer disease</Keyword>
            <Keyword MajorTopicYN="Y">blood pressure</Keyword>
            <Keyword MajorTopicYN="Y">disease progression</Keyword>
            <Keyword MajorTopicYN="Y">hippocampus</Keyword>
            <Keyword MajorTopicYN="Y">nilvadipine</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31203725</ArticleId>
            <ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.12892</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">31102579</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>04</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-6254</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>196</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Acta tropica</Title>
                <ISOAbbreviation>Acta Trop.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Toxoplasma gondii infection and risk of Parkinson and Alzheimer diseases: A systematic review and meta-analysis on observational studies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>165-171</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0001-706X(18)31415-3</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.actatropica.2019.05.015</ELocationID>
            <Abstract>
                <AbstractText>In the past decade, Toxoplasma gondii infection has been recognized as a potential risk for many psychiatric and neurological disorders. We performed this systematic review and meta-analysis to evaluate the association between Toxoplasma infection and Parkinson's and Alzheimer's diseases. PubMed, Web of science, Scopus and Embase databases were searched up to September 30, 2018 for studies that reported risk of Parkinson's and Alzheimer's diseases associated with Toxoplasma infection. We used a random effects meta-analysis model to generate the pooled odds ratio (OR) with 95% confidence intervals (CIs). Eleven studies, including seven studies for Parkinson's disease (428 patients and 540 controls) and four studies for Alzheimer's disease (301 patients and 313 controls), were included in the meta-analysis. We found that there was no statistically significant association between Toxoplasma infection, as determined by IgG serology, IgM serology, and PCR with increased risk of Parkinson's disease (OR, 1.14; 95% CI, 0.78-1.68), (OR, 1.61; 95% CI, 0.33-7.76) and (OR, 1.87; 95% CI, 0.43-8.05), respectively. The OR for association of Toxoplasma infection, based on IgG serology with Alzheimer's patients, compared to control group, was (OR, 1.38; 95% CI, 0.99-1.92), demonstrating a marginally significant association between Toxoplasma infection and Alzheimer's disease. Our findings do not support a general hypotheses regarding an associative relationship between Toxoplasma infection and Parkinson's disease, but do support a marginally significant association between Toxoplasma infection and Alzheimer's disease; this association should be investigated further through longitudinal and experimental studies.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bayani</LastName>
                    <ForeName>Masomeh</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Riahi</LastName>
                    <ForeName>Seyed Mohammad</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Social Determinants of Health Research Center, Department of Epidemiology and Biostatistics, Faculty of Health, Birjand University of Medical Sciences, Birjand, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bazrafshan</LastName>
                    <ForeName>Negar</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ray Gamble</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>National Academy of Sciences, Washington, DC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rostami</LastName>
                    <ForeName>Ali</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; Immunoregulation Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. Electronic address: alirostami1984@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D000078182">Systematic Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>15</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Acta Trop</MedlineTA>
            <NlmUniqueID>0370374</NlmUniqueID>
            <ISSNLinking>0001-706X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000913">Antibodies, Protozoan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000913" MajorTopicYN="N">Antibodies, Protozoan</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014123" MajorTopicYN="N">Toxoplasmosis</DescriptorName>
                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer</Keyword>
            <Keyword MajorTopicYN="N">Association</Keyword>
            <Keyword MajorTopicYN="N">Meta-analysis</Keyword>
            <Keyword MajorTopicYN="N">Parkinson</Keyword>
            <Keyword MajorTopicYN="N">Toxoplasma gondii infection</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>04</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31102579</ArticleId>
            <ArticleId IdType="pii">S0001-706X(18)31415-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.actatropica.2019.05.015</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31096454</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1536-5964</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>98</Volume>
                    <Issue>20</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Medicine</Title>
                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of Alzheimer disease in old major depressive patients based upon their health status: A retrospective study in Taiwan.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e15527</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000015527</ELocationID>
            <Abstract>
                <AbstractText>This study is conducted to investigate the association between major depressive disorder and the subsequent development of Alzheimer disease (AD) in elderly patients with different health statuses using Taiwan's National Health Insurance Research Database (NHIRD).A retrospective cohort study was performed on subjects over 65 years old from 2002 to 2006 using a random sampling from the 1 million beneficiaries enrolled in the NHI. Patients who were diagnosed with major depressive disorder were selected as the case group. Subjects in the control group were selected from elderly patients who did not have depression during the study period by matching age, sex, and index date of depression with subjects in the case group using a ratio of 1:4 (case:control). Both groups of patients were checked annually over a period of 7 years to observe whether they subsequently developed AD.A total of 1776 subjects were included in the case group while 7104 subjects were in the control group. After the follow-up period, 59 patients (3.3%) with depression developed AD while 96 patients (1.4%) without depression developed AD. The Kaplan-Meier curves showed that the incidence rate of AD in both groups varied significantly depending on different health statuses (log-rank P &lt; .001). Results of the generalized estimating equation model found that patients with depression (hazard ratio [HR] = 1.898; 95% confidence interval [CI] = 1.451-2.438), very severe health status (HR = 1.630; 95% CI = 1.220-2.177), or artery diseases (HR = 1.692; 95% CI = 1.108-2.584) were at a higher risk of developing AD than other groups.The association between major depressive disorder and the later development of AD varied depending on the health statuses of elderly patients. Clinicians should exercise caution when diagnosing and treating underlying diseases in elderly depressed patients, and then attempt to improve their health status to reduce the incidence rate of subsequent AD development.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tao</LastName>
                    <ForeName>Ping</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Affair and Planning, Taipei Veterans General Hospital.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Health Policy and Management, College of Public Health, National Taiwan University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Szu-Nian</ForeName>
                    <Initials>SN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Superintendent Office, Tri-Service General Hospital Beitou Branch.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Institute of Health and Welfare Policy, National Yang-Ming University.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, National Defense Medical Center, Taipei, Taiwan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tung</LastName>
                    <ForeName>Yu-Chi</ForeName>
                    <Initials>YC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Health Policy and Management, College of Public Health, National Taiwan University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Ming-Chin</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Health Policy and Management, College of Public Health, National Taiwan University.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Medicine (Baltimore)</MedlineTA>
            <NlmUniqueID>2985248R</NlmUniqueID>
            <ISSNLinking>0025-7974</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009313" MajorTopicYN="N">National Health Programs</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31096454</ArticleId>
            <ArticleId IdType="doi">10.1097/MD.0000000000015527</ArticleId>
            <ArticleId IdType="pii">00005792-201905170-00025</ArticleId>
            <ArticleId IdType="pmc">PMC6531098</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30936769</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1958-5969</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>12</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Dialogues in clinical neuroscience</Title>
                <ISOAbbreviation>Dialogues Clin Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease?</ArticleTitle>
            <Pagination>
                <MedlinePgn>293-300</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Alzheimer disease (AD) is the major epidemic of the 21<sup>st</sup> century, its prevalence rising along with improved human longevity. Early AD diagnosis is key to successful treatment, as currently available therapeutics only allow small benefits for diagnosed AD patients. By contrast, future therapeutics, including those already in preclinical or clinical trials, are expected to afford neuroprotection prior to widespread brain damage and dementia. Brain imaging technologies are developing as promising tools for early AD diagnostics, yet their high cost limits their utility for screening at-risk populations. Blood or plasma transcriptomics, proteomics, and/or metabolomics may pave the way for cost-effective AD risk screening in middle-aged individuals years ahead of cognitive decline. This notion is exemplified by data mining of blood transcriptomics from a published dataset. Consortia blood sample collection and analysis from large cohorts with mild cognitive impairment followed longitudinally for their cognitive state would allow the development of a reliable and inexpensive early AD screening tool.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hadar</LastName>
                    <ForeName>Adva</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gurwitz</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine; Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv 69978 Israel.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Dialogues Clin Neurosci</MedlineTA>
            <NlmUniqueID>101238198</NlmUniqueID>
            <ISSNLinking>1294-8322</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D042241" MajorTopicYN="Y">Early Diagnosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D059906" MajorTopicYN="Y">Neuroimaging</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherAbstract Type="Publisher" Language="spa">
            <AbstractText>La Enfermedad de Alzheimer (EA) es la principal epidemia del siglo XXI y su prevalencia está aumentando con el incremento de la longevidad humana. El diagnóstico precoz de la EA es clave para un tratamiento exitoso, ya que las terapias actualmente disponibles sólo permiten pequeños beneficios para los pacientes diagnosticados con EA. Al contrario, se espera que las futuras terapias, incluyendo las que ya están en ensayos preclínicos o clínicos, proporcionen una neuroprotección previo al daño cerebral generalizado y demencia. Las tecnologías de imágenes cerebrales se están desarrollando como prometedoras herramientas para diagnósticos precoces de la EA, aunque todavía su alto costo limita su empleo como evaluación en poblaciones en riesgo. La transcriptómica, proteómica ylo metabolómica sanguínea o plasmática pueden abrir la vía para una evaluación económica del riesgo de EA en individuos de edad media años antes del deterioro cognitivo. Este concepto está ilustrado por la explotación de datos de transcriptomas sanguíneos provenientes de una base de datos publicada. Un consorcio de recolección de muestras sanguíneas y de análisis de grandes cohortes con deterioro cognitivo leve, seguidas longitudinalmente en su estado cognitivo podría permitir el desarrollo de una herramienta de evaluación precoz de la EA que sea confiable y de bajo costo.</AbstractText>
        </OtherAbstract>
        <OtherAbstract Type="Publisher" Language="fre">
            <AbstractText>La prévalence de la maladie d'Alzheimer (MA), épidémie principale du XXIe siècle, augmente avec l'augmentation de l'espérance de vie. Les traitements actuellement disponibles n'apportant que de faibles bénéfices pour les patients atteints, un diagnostic précoce de la maladie est essentiel pour la traiter efficacement. A l'avenir, les traitements (y compris ceux déjà en essais cliniques ou précliniques) devront assurer une protection neuronale avant même l'apparition de lésions cérébrales étendues et de signes de démence. Les techniques d'imagerie cérébrale sont des outils prometteurs pour le diagnostic précoce de MA mais leur coût élevé limite leur utilisation pour le dépistage des populations à risque. La métabolomique, la protéomique et/ou la transcritomique sanguines ou plasmatiques peuvent ouvrir la voie d'un dépistage à moindre coût du risque de MA chez des sujets d'âge moyen, des années avant le déclin cognitif. L'exploitation des données de transcriptomes sanguins à partir d'une base de données publiées, en est l'illustration. Un consortium de recueil d'échantillons sanguins et d'analyses à partir de grandes cohortes de sujets atteints de troubles cognitifs légers dont l'état cognitif est suivi longitudinalement permettra le développement d'un outil de dépistage précoce de la MA fiable et peu coûteux.</AbstractText>
        </OtherAbstract>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Alzheimer disease</Keyword>
            <Keyword MajorTopicYN="Y">bioinformatics</Keyword>
            <Keyword MajorTopicYN="Y">mild cognitive impairment</Keyword>
            <Keyword MajorTopicYN="Y">proteomics</Keyword>
            <Keyword MajorTopicYN="Y">transcriptomics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30936769</ArticleId>
            <ArticleId IdType="pmc">PMC6436957</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Res Ther. 2018 Jan 15;10(1):5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29370833</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2018;64(s1):S33-S39</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29758942</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Dement (Amst). 2017 May 26;8:131-138</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28649597</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Curr Opin Neurol. 2017 Dec;30(6):623-629</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29095718</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Dement. 2018 Nov;14(11):1470-1481</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29499171</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Rep. 2018 May 31;8(1):8465</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29855513</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Clin Transl Neurol. 2018 May 24;5(7):832-842</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30009200</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Med. 2013 May 14;5(5):41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23672693</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Phys Rev Lett. 2018 Mar 23;120(12):128101</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29694095</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neurol Ther. 2017 Jul;6(Suppl 1):15-24</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28733960</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cardiovasc Res. 2018 Jul 15;114(9):1241-1257</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29617720</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Aging Neurosci. 2013 Nov 05;5:64</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24204343</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Aging Neurosci. 2018 Jun 21;10:191</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29977201</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>JAMA Intern Med. 2018 Aug 1;178(8):1086-1097</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29971434</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Neurobiol Aging. 2018 Oct;70:125-127</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30007161</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Aging Neurosci. 2018 May 24;10:152</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29881343</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2011;27(2):299-305</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21841250</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Int Neurourol J. 2014 Jun;18(2):50-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24987556</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Dement (N Y). 2018 May 03;4:182-194</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29955662</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Dement (N Y). 2018 May 03;4:195-214</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29955663</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2018 Jul;50(7):968-978</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29915430</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Neurosci. 2018 Feb 06;12:37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29467605</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Cochrane Database Syst Rev. 2017 Mar 22;3:CD010803</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28328043</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2018 Jul;50(7):920-927</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29942085</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Transl Psychiatry. 2016 Oct 4;6(10):e909</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27701409</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Investig. 1994 Feb;72(3):196-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7516751</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Brain. 2018 Jul 1;141(7):1917-1933</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29850777</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Proc. 2009 Dec 15;3 Suppl 7:S92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20018089</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Mol Neurosci. 2018 Jul;65(3):289-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29956088</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2018;64(1):323-335</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29889075</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Med (Lausanne). 2018 Apr 24;5:108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29740579</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Mol Ecol. 2016 Mar;25(6):1224-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26756714</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Trends Neurosci. 2018 Sep;41(9):587-598</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29885742</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Expert Rev Proteomics. 2017 Oct;14(10):845-855</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28918672</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Clin Transl Neurol. 2016 May 11;3(6):455-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27547773</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Eur J Clin Invest. 2018 Oct;48(10):e13005</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30028503</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2018;62(3):913-932</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29562532</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2016 Dec 6;55(3):1175-1182</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">27792013</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2011 May;43(5):491-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21478889</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Prev Alzheimers Dis. 2016 Dec;3(4):243-259</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28344933</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Biochim Biophys Acta. 2016 Jun;1862(6):1084-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26957286</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Value Health. 2018 Mar;21(3):295-303</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29566836</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Dement. 2017 Oct;13(10):1107-1116</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28322202</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Alzheimers Dement (Amst). 2017 Sep 06;8:196-207</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28951883</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Clin Biochem. 2018 Sep;59:9-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29920246</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Biol. 2015 Sep 07;16:185</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26343147</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Genome Med. 2015 Jul 03;7(1):67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26221186</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lancet Neurol. 2017 Aug;16(8):661-676</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28721928</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Methods Mol Biol. 2018;1793:37-49</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29876890</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2018;64(s1):S289-S297</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29614671</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Clin Psychiatry. 2007 Apr;68(4):613-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17474819</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7285-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26060301</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Curr Alzheimer Res. 2013 Oct;10(8):852-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23919770</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2018 Jul;50(7):912-919</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29942086</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2018;63(2):783-796</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29689725</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Pharmacol Res. 2018 Apr;130:331-365</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29458203</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Sci Rep. 2017 Jul 5;7(1):4660</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28680085</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Expert Rev Precis Med Drug Dev. 2017;2(1):47-55</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28944295</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Neurochem. 2017 Nov;143(4):396-408</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">28397252</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Pharmacogenomics. 2010 Apr;11(4):469-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20350123</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>BMC Neurol. 2010 Nov 03;10:108</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21047401</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Drug Dev Res. 2014 Aug;75(5):267-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25160066</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2018 Jul;50(7):928-936</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29892016</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Alzheimers Dis. 2018;62(3):1211-1218</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29562539</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>J Gerontol A Biol Sci Med Sci. 2009 Jun;64(6):636-45</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19366883</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Front Aging Neurosci. 2018 Jun 22;10:188</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29988470</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Ann Transl Med. 2018 Apr;6(8):157</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29862246</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nat Genet. 2018 Aug;50(8):1072-1080</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">30013184</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Lab Chip. 2018 Jan 30;18(3):395-405</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">29192299</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2011 Oct 26;478(7370):519-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22031444</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
        <ReferenceList>
            <Reference>
                <Citation>Nature. 2008 Feb 21;451(7181):949-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18288185</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30927917</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>07</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>07</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-511X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Mar</Month>
                        <Day>30</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Lipids in health and disease</Title>
                <ISOAbbreviation>Lipids Health Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The sociodemographic characteristics and dietary and blood plasma fatty acid profiles of elderly Saudi women with Alzheimer disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>77</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12944-019-1029-0</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease (AD) is a progressive neurodegenerative disease, and due to various physiological and psychological factors the patients are at risk of nutritional insufficiencies. The purpose of this study was to assess the dietary fatty acid intake and its effect on plasma fatty acids in elderly Saudi women and to compare the differences in their food and plasma fatty acid profile on the basis of their residence.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 76 elderly women (50-100 years) were recruited through a random sampling method. A structured proforma was designed to gather information related to their age, income, dietary habits, and presence of any disease and awareness of AD. A 24-h dietary recall method for 3 days and food frequency questionnaire, concentrating on fish consumption and consumption of foods rich in ω-3 fatty acids, which was planned by dietitians, was used for dietary assessment. The gathered data were then analyzed using food processor software. The blood samples were collected to determine plasma fatty acids.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean age of women diagnosed with AD was more than 75 years, and the prevalence of illiteracy was higher among AD subjects. As compared to the AD group, the concentration of LA and total ω-6 was significantly (p ≤ 0.05) higher in the control group from both recruitment sites [National Guard Health Affairs, King Abdulaziz Medical City, Riyadh (NGH) and Social Welfare Homes for the Elderly (SWH)]. Similarly, the concentrations of EPA, DHA, and ω-3 were also slightly higher in the control group at both sites, but the difference between the control and AD subjects was only significant (p ≤ 0.05) in subjects from NGH. We found no significant difference in the ω-6/ ω-3 ratio between groups. Also, no significant difference was found in the mean level of the plasma fatty acid when comparing the control and AD groups. The concentration of DHA in controls only and AA, EPA and ω-6 in both control and AD were significant (although weakly) correlated with their respective dietary intakes. No correlations were found between the intake of 18 C precursors (LA and ALA) and plasma levels of their long chain derivatives (AA, EPA, and DHA). Education, income, overall health status and the concentration of various fatty acids from food was higher and better in subjects from SWH than NGH. The lower plasma level indicates lower impaired systemic availability of several nutrients.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We found that dietary intervention might play a role in the prevention of AD.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Alsumari</LastName>
                    <ForeName>Samar Rashed</ForeName>
                    <Initials>SR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Food and Nutrition Sciences, College of Food and Agriculture Sciences, King Saud University, Riyadh-11495, P.O. 11495, Riyadh, Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>AlNouri</LastName>
                    <ForeName>Doha Mustafa</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Food and Nutrition Sciences, College of Food and Agriculture Sciences, King Saud University, Riyadh-11495, P.O. 11495, Riyadh, Saudi Arabia. dohaalnouri@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>El-Sayed</LastName>
                    <ForeName>Mervat Mohamed Ali</ForeName>
                    <Initials>MMA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Food and Nutrition Sciences, College of Food and Agriculture Sciences, King Saud University, Riyadh-11495, P.O. 11495, Riyadh, Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>El-Din</LastName>
                    <ForeName>Mohamed Fekry Serag</ForeName>
                    <Initials>MFS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Food and Nutrition Sciences, College of Food and Agriculture Sciences, King Saud University, Riyadh-11495, P.O. 11495, Riyadh, Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Nutrition and Food Science, Faculty of Home Economics, Menoufia University, Shebin El Kom, Egypt.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arzoo</LastName>
                    <ForeName>Shaista</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Food and Nutrition Sciences, College of Food and Agriculture Sciences, King Saud University, Riyadh-11495, P.O. 11495, Riyadh, Saudi Arabia.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>A-B-36-276</GrantID>
                    <Agency>King Abdulaziz City for Science and Technology (SA)</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Lipids Health Dis</MedlineTA>
            <NlmUniqueID>101147696</NlmUniqueID>
            <ISSNLinking>1476-511X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>25167-62-8</RegistryNumber>
                <NameOfSubstance UI="D004281">Docosahexaenoic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AAN7QOV9EA</RegistryNumber>
                <NameOfSubstance UI="D015118">Eicosapentaenoic Acid</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004032" MajorTopicYN="Y">Diet</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004281" MajorTopicYN="N">Docosahexaenoic Acids</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015118" MajorTopicYN="N">Eicosapentaenoic Acid</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005247" MajorTopicYN="N">Feeding Behavior</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012529" MajorTopicYN="N" Type="Geographic">Saudi Arabia</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017747" MajorTopicYN="N">Seafood</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer</Keyword>
            <Keyword MajorTopicYN="N">Brain</Keyword>
            <Keyword MajorTopicYN="N">Correlation</Keyword>
            <Keyword MajorTopicYN="N">Diet</Keyword>
            <Keyword MajorTopicYN="N">Fatty acids</Keyword>
            <Keyword MajorTopicYN="N">Plasma</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>7</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30927917</ArticleId>
            <ArticleId IdType="doi">10.1186/s12944-019-1029-0</ArticleId>
            <ArticleId IdType="pii">10.1186/s12944-019-1029-0</ArticleId>
            <ArticleId IdType="pmc">PMC6441169</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30924900</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2574-3805</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>03</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA network open</Title>
                <ISOAbbreviation>JAMA Netw Open</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association of Rare Coding Mutations With Alzheimer Disease and Other Dementias Among Adults of European Ancestry.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e191350</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2019.1350</ELocationID>
            <Abstract>
                <AbstractText Label="Importance">Some of the unexplained heritability of Alzheimer disease (AD) may be due to rare variants whose effects are not captured in genome-wide association studies because very large samples are needed to observe statistically significant associations.</AbstractText>
                <AbstractText Label="Objective">To identify genetic variants associated with AD risk using a nonstatistical approach.</AbstractText>
                <AbstractText Label="Design, Setting, and Participants">Genetic association study in which rare variants were identified by whole-exome sequencing in unrelated individuals of European ancestry from the Alzheimer's Disease Sequencing Project (ADSP). Data were analyzed between March 2017 and September 2018.</AbstractText>
                <AbstractText Label="Main Outcomes and Measures">Minor alleles genome-wide and in 95 genes previously associated with AD, AD-related traits, or other dementias were tabulated and filtered for predicted functional impact and occurrence in participants with AD but not controls. Support for several findings was sought in a whole-exome sequencing data set comprising 19 affected relative pairs from Utah high-risk pedigrees and whole-genome sequencing data sets from the ADSP and Alzheimer's Disease Neuroimaging Initiative.</AbstractText>
                <AbstractText Label="Results">Among 5617 participants with AD (3202 [57.0%] women; mean [SD] age, 76.4 [9.3] years) and 4594 controls (2719 [59.0%] women; mean [SD] age, 86.5 [4.5] years), a total of 24 variants with moderate or high functional impact from 19 genes were observed in 10 or more participants with AD but not in controls. These variants included a missense mutation (rs149307620 [p.A284T], n = 10) in NOTCH3, a gene in which coding mutations are associated with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), that was also identified in 1 participant with AD and 1 participant with mild cognitive impairment in the whole genome sequencing data sets. Four participants with AD carried the TREM2 rs104894002 (p.Q33X) high-impact mutation that, in homozygous form, causes Nasu-Hakola disease, a rare disorder characterized by early-onset dementia and multifocal bone cysts, suggesting an intermediate inheritance model for the mutation. Compared with controls, participants with AD had a significantly higher burden of deleterious rare coding variants in dementia-associated genes (2314 vs 3354 cumulative variants, respectively; P = .006).</AbstractText>
                <AbstractText Label="Conclusions and Relevance">Different mutations in the same gene or variable dose of a mutation may be associated with result in distinct dementias. These findings suggest that minor differences in the structure or amount of protein may be associated with in different clinical outcomes. Understanding these genotype-phenotype associations may provide further insight into the pathogenic nature of the mutations, as well as offer clues for developing new therapeutic targets.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Devanshi</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics Graduate Program, Boston University, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mez</LastName>
                    <ForeName>Jesse</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vardarajan</LastName>
                    <ForeName>Badri N</ForeName>
                    <Initials>BN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Staley</LastName>
                    <ForeName>Lyndsay</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Brigham Young University, Provo, Utah.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chung</LastName>
                    <ForeName>Jaeyoon</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics Graduate Program, Boston University, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaoling</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farrell</LastName>
                    <ForeName>John J</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rynkiewicz</LastName>
                    <ForeName>Michael J</ForeName>
                    <Initials>MJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Physiology &amp; Biophysics, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cannon-Albright</LastName>
                    <ForeName>Lisa A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Huntsman Cancer Institute, Salt Lake City, Utah.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teerlink</LastName>
                    <ForeName>Craig C</ForeName>
                    <Initials>CC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stevens</LastName>
                    <ForeName>Jeffery</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corcoran</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Mathematics and Statistics, Utah State University, Logan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonzalez Murcia</LastName>
                    <ForeName>Josue D</ForeName>
                    <Initials>JD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Brigham Young University, Provo, Utah.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lopez</LastName>
                    <ForeName>Oscar L</ForeName>
                    <Initials>OL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mayeux</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haines</LastName>
                    <ForeName>Jonathan L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Population &amp; Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pericak-Vance</LastName>
                    <ForeName>Margaret A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, Florida.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schellenberg</LastName>
                    <ForeName>Gerard</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kauwe</LastName>
                    <ForeName>John S K</ForeName>
                    <Initials>JSK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biology, Brigham Young University, Provo, Utah.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lunetta</LastName>
                    <ForeName>Kathryn L</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Farrer</LastName>
                    <ForeName>Lindsay A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics Graduate Program, Boston University, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>Alzheimer’s Disease Sequencing Project</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K23 AG046377</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AG048927</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 AG013846</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RF1 AG057519</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AG032984</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 AG033193</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UF1 AG047133</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AG049505</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AG049506</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AG049507</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AG049508</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AG052409</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AG052410</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 AG052411</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U54 AG052427</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA Netw Open</MedlineTA>
            <NlmUniqueID>101729235</NlmUniqueID>
            <ISSNLinking>2574-3805</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000071656">Receptor, Notch3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000071656" MajorTopicYN="N">Receptor, Notch3</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30924900</ArticleId>
            <ArticleId IdType="pii">2729478</ArticleId>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2019.1350</ArticleId>
            <ArticleId IdType="pmc">PMC6450321</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30924889</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2574-3805</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>03</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA network open</Title>
                <ISOAbbreviation>JAMA Netw Open</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association of Neuropathologically Confirmed Frontotemporal Dementia and Alzheimer Disease With Criminal and Socially Inappropriate Behavior in a Swedish Cohort.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e190261</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2019.0261</ELocationID>
            <Abstract>
                <AbstractText Label="Importance">Criminal and socially inappropriate behavior is encountered among patients with dementia, and it is sometimes the first sign of a dementing disorder. This behavior constitutes a significant burden to society, patients' relatives, and patients themselves.</AbstractText>
                <AbstractText Label="Objectives">To investigate and compare the prevalence and type of criminal and socially inappropriate behavior, as well as recurrence of criminal behavior, associated with Alzheimer disease (AD) and frontotemporal dementia (FTD) neuropathologically verified post mortem, and to assess whether there is a specific type of protein pathology more closely associated with criminal behavior in patients with FTD.</AbstractText>
                <AbstractText Label="Design, Setting, and Participants">Cohort study using medical record review of 220 Swedish patients with a postmortem neuropathologic diagnosis of AD (n = 101) or frontotemporal lobar degeneration (n = 119) (hereinafter referred to as FTD) diagnosed between January 1, 1967, and December 31, 2017.</AbstractText>
                <AbstractText Label="Main Outcomes and Measures">Patient notes containing reports of criminal and socially inappropriate behavior, as well as data on dominant protein pathology for patients with FTD, were duly reviewed and recorded. The Fisher exact test or logistic regression was used to assess possible differences between groups.</AbstractText>
                <AbstractText Label="Results">Of the 220 patients studied, 128 (58.2%) were female, the median (range) age at disease onset was 63 (30-88) years and at death was 72 (34-96) years, and the median (range) disease duration was 9 (1-28) years. Instances of criminal behavior were found in 65 of the 220 patients (29.5%): in 15 of the 101 patients (14.9%) with AD and 50 of the 119 patients (42.0%) with FTD (P &lt; .001). Recurrence of criminal behavior was significantly higher in the FTD group (89.0%) than in the AD group (53.3%) (P = .04). Instances of socially inappropriate behavior were found in 57 patients (56.4%) with AD and 89 (74.8%) with FTD (P = .004). An expression of non-tau pathology increased the odds for criminal behavior by a factor of 9.0 (95% CI, 3.4-24.0) among patients with FTD.</AbstractText>
                <AbstractText Label="Conclusions and Relevance">These results suggest that criminal and socially inappropriate behaviors may be more prevalent and criminal behaviors may be more recurrent in patients with FTD than in those with AD. Non-tau pathology, but not tau pathology, appears to be associated with criminal behavior. These findings may help with the clinical diagnostic process.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Liljegren</LastName>
                    <ForeName>Madeleine</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Region Skåne, Sweden.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics and Pathology, Medical Service, Region Skåne, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Landqvist Waldö</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Clinical Sciences, Helsingborg, Department of Clinical Sciences, Lund University, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Frizell Santillo</LastName>
                    <ForeName>Alexander</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ullén</LastName>
                    <ForeName>Susann</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Studies Sweden-Forum South, Skåne University Hospital, Lund, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rydbeck</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Forensic Psychiatry, Trelleborg, Region Skåne, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Miller</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Englund</LastName>
                    <ForeName>Elisabet</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Region Skåne, Sweden.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Genetics and Pathology, Medical Service, Region Skåne, Sweden.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA Netw Open</MedlineTA>
            <NlmUniqueID>101729235</NlmUniqueID>
            <ISSNLinking>2574-3805</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000066479" MajorTopicYN="N">Criminal Behavior</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003933" MajorTopicYN="N">Diagnosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069338" MajorTopicYN="N">Neuropathology</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30924889</ArticleId>
            <ArticleId IdType="pii">2729467</ArticleId>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2019.0261</ArticleId>
            <ArticleId IdType="pmc">PMC6450313</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30875345</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>27</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1537-162X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>42</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <MedlineDate>2019 Mar/Apr</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical neuropharmacology</Title>
                <ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Donepezil's Effects on Brain Functions of Patients With Alzheimer Disease: A Regional Homogeneity Study Based on Resting-State Functional Magnetic Resonance Imaging.</ArticleTitle>
            <Pagination>
                <MedlinePgn>42-48</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/WNF.0000000000000324</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Donepezil is known to increase cholinergic synaptic transmission in Alzheimer disease (AD), although how it affects cortical brain activity and how it consequently affects brain functions need further clarification. To investigate the therapeutic mechanism of donepezil underlying its effect on brain function, regional homogeneity (ReHo) technology was used in this study.</AbstractText>
                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This study included 11 mild-to-moderate AD patients who completed 24 weeks of donepezil treatment and 11 matched healthy controls. All participants finished neuropsychological assessment and resting-state functional magnetic resonance imaging scanning to compare whole-brain ReHo before and after donepezil treatment.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Significantly decreased Alzheimer's Disease Assessment Scale-Cognitive Subscale scores (P = 0.010) and increased Mini-Mental State Examination scores (P = 0.043) were observed in the AD patients. In addition, in the right gyrus rectus (P = 0.021), right precentral gyrus (P = 0.026), and left superior temporal gyrus (P = 0.043) of the AD patients, decreased ReHo was exhibited.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Donepezil-mediated improvement of cognitive function in AD patients is linked to spontaneous brain activities of the right gyrus rectus, right precentral gyrus, and left superior temporal gyrus, which could be used as potential biomarkers for monitoring the therapeutic effect of donepezil.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cheng</LastName>
                    <ForeName>Jianan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jiangtao</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Neuropharmacol</MedlineTA>
            <NlmUniqueID>7607910</NlmUniqueID>
            <ISSNLinking>0362-5664</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8SSC91326P</RegistryNumber>
                <NameOfSubstance UI="D000077265">Donepezil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077265" MajorTopicYN="N">Donepezil</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012146" MajorTopicYN="N">Rest</DescriptorName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30875345</ArticleId>
            <ArticleId IdType="doi">10.1097/WNF.0000000000000324</ArticleId>
            <ArticleId IdType="pii">00002826-201903000-00005</ArticleId>
            <ArticleId IdType="pmc">PMC6426347</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30865678</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Deep convolutional neural networks for segmenting 3D in vivo multiphoton images of vasculature in Alzheimer disease mouse models.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0213539</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0213539</ELocationID>
            <Abstract>
                <AbstractText>The health and function of tissue rely on its vasculature network to provide reliable blood perfusion. Volumetric imaging approaches, such as multiphoton microscopy, are able to generate detailed 3D images of blood vessels that could contribute to our understanding of the role of vascular structure in normal physiology and in disease mechanisms. The segmentation of vessels, a core image analysis problem, is a bottleneck that has prevented the systematic comparison of 3D vascular architecture across experimental populations. We explored the use of convolutional neural networks to segment 3D vessels within volumetric in vivo images acquired by multiphoton microscopy. We evaluated different network architectures and machine learning techniques in the context of this segmentation problem. We show that our optimized convolutional neural network architecture with a customized loss function, which we call DeepVess, yielded a segmentation accuracy that was better than state-of-the-art methods, while also being orders of magnitude faster than the manual annotation. To explore the effects of aging and Alzheimer's disease on capillaries, we applied DeepVess to 3D images of cortical blood vessels in young and old mouse models of Alzheimer's disease and wild type littermates. We found little difference in the distribution of capillary diameter or tortuosity between these groups, but did note a decrease in the number of longer capillary segments (&gt;75μm) in aged animals as compared to young, in both wild type and Alzheimer's disease mouse models.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Haft-Javaherian</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">0000-0002-8551-5008</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fang</LastName>
                    <ForeName>Linjing</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Muse</LastName>
                    <ForeName>Victorine</ForeName>
                    <Initials>V</Initials>
                    <Identifier Source="ORCID">0000-0003-1583-6970</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schaffer</LastName>
                    <ForeName>Chris B</ForeName>
                    <Initials>CB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nishimura</LastName>
                    <ForeName>Nozomi</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sabuncu</LastName>
                    <ForeName>Mert R</ForeName>
                    <Initials>MR</Initials>
                    <Identifier Source="ORCID">0000-0002-7068-719X</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, United States of America.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>School of Electrical and Computer Engineering, Cornell University, Ithaca, NY, United States of America.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 AG053949</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 LM012719</GrantID>
                    <Acronym>LM</Acronym>
                    <Agency>NLM NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R21 AG050122</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002533" MajorTopicYN="Y">Cerebral Angiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002540" MajorTopicYN="Y">Cerebral Cortex</DescriptorName>
                <QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D021621" MajorTopicYN="Y">Imaging, Three-Dimensional</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D036641" MajorTopicYN="Y">Microscopy, Fluorescence, Multiphoton</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016571" MajorTopicYN="Y">Neural Networks (Computer)</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>12</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30865678</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0213539</ArticleId>
            <ArticleId IdType="pii">PONE-D-18-30096</ArticleId>
            <ArticleId IdType="pmc">PMC6415838</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30821828</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2574-3805</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>03</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA network open</Title>
                <ISOAbbreviation>JAMA Netw Open</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e190213</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2019.0213</ELocationID>
            <Abstract>
                <AbstractText Label="Importance">To date, no study has compared time to skilled nursing facility (SNF) admission and cardiovascular events across medications available to treat Alzheimer disease.</AbstractText>
                <AbstractText Label="Objective">To compare time to SNF admission and cardiovascular events between acetylcholinesterase inhibitor (AChEI) monotherapy, memantine hydrochloride monotherapy, and combination therapy with an AChEI and memantine in treating elderly adults with Alzheimer disease.</AbstractText>
                <AbstractText Label="Design, Setting, and Participants">This retrospective cohort study uses January 1, 2006, to December 31, 2014, claims data from a 5% random sample of Medicare beneficiaries who had received a new diagnosis of Alzheimer disease between January 1, 2007, and December 31, 2013, and who initiated AChEI monotherapy, memantine monotherapy, or combination therapy with an AChEI and memantine (N = 73 475). Patients were followed up until discontinuation of treatment, switch of treatment, death, or the end of the study period. Statistical analysis was conducted from February 15, 2018, to June 15, 2018.</AbstractText>
                <AbstractText Label="Exposures">Acetylcholinesterase inhibitor monotherapy (n = 44 424), memantine monotherapy (n = 11 809), and combination therapy with an AChEI and memantine (n = 17 242).</AbstractText>
                <AbstractText Label="Main Outcomes and Measures">Primary outcomes were time to SNF admission and the composite of the following cardiovascular events: acute myocardial infarction, bradycardia, syncope, atrioventricular block, QT interval prolongation, and ventricular tachycardia. Cox proportional hazards regression models were constructed to compare outcomes between each pair of treatment groups, controlling for a comprehensive list of patient characteristics.</AbstractText>
                <AbstractText Label="Results">The study population included 73 475 participants (53 068 women and 20 407 men; mean [SD] age, 81.8 [8.3] years); 25.5% of the participants initiating AChEI monotherapy, 25.6% of participants initiating memantine monotherapy, and 29.7% of participants initiating combination therapy with an AChEI and memantine were admitted to an SNF. Similarly, 22.2% of the participants initiating AChEI monotherapy, 20.0% of those initiating memantine monotherapy, and 24.5% of those initiating combination therapy experienced at least 1 cardiovascular event. No difference in time to SNF admission was found across the 3 treatment groups. The risk of the composite measure of any cardiovascular event did not differ between the combination therapy and AChEI monotherapy groups (adjusted hazard ratio [aHR], 0.99; 95% CI, 0.96-1.03); however, it was higher for both AChEI monotherapy (aHR, 1.07; 95% CI, 1.02-1.12) and combination therapy (aHR, 1.07; 95% CI, 1.01-1.12), relative to memantine monotherapy. This result was mainly driven by the lower risk of bradycardia and syncope observed for the memantine monotherapy group relative to both AChEI monotherapy (bradycardia: aHR, 0.88; 95% CI, 0.82-0.95; and syncope: aHR, 0.92; 95% CI, 0.86-0.97) and combination therapy (bradycardia: aHR, 0.89; 95% CI, 0.82-0.97; and syncope: aHR, 0.87; 95% CI, 0.83-0.94).</AbstractText>
                <AbstractText Label="Conclusions and Relevance">Time to SNF admission did not differ across treatment groups, but memantine monotherapy was associated with a lower risk of cardiovascular events compared with both AChEI monotherapy and combination therapy with an AChEI and memantine.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>San-Juan-Rodriguez</LastName>
                    <ForeName>Alvaro</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yuting</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Melbourne Institute, Faculty of Business and Economics, University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Meiqi</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hernandez</LastName>
                    <ForeName>Inmaculada</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K01 HL142847</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA Netw Open</MedlineTA>
            <NlmUniqueID>101729235</NlmUniqueID>
            <ISSNLinking>2574-3805</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>W8O17SJF3T</RegistryNumber>
                <NameOfSubstance UI="D008559">Memantine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057915" MajorTopicYN="N">Drug Substitution</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007326" MajorTopicYN="Y">Institutionalization</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010043" MajorTopicYN="N">Outcome and Process Assessment (Health Care)</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012866" MajorTopicYN="N">Skilled Nursing Facilities</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D028761" MajorTopicYN="N">Withholding Treatment</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30821828</ArticleId>
            <ArticleId IdType="pii">2726715</ArticleId>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2019.0213</ArticleId>
            <ArticleId IdType="pmc">PMC6484658</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30786875</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2202</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>20</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC neuroscience</Title>
                <ISOAbbreviation>BMC Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Astrocytes infected with Chlamydia pneumoniae demonstrate altered expression and activity of secretases involved in the generation of β-amyloid found in Alzheimer disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12868-019-0489-5</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Epidemiologic studies strongly suggest that the pathophysiology of late-onset Alzheimer disease (AD) versus early-onset AD has environmental rather than genetic causes, thus revealing potentially novel therapeutic targets to limit disease progression. Several studies supporting the &quot;pathogen hypothesis&quot; of AD demonstrate a strong association between pathogens and the production of β-amyloid, the pathologic hallmark of AD. Although the mechanism of pathogen-induced neurodegeneration of AD remains unclear, astrocytes, a key player of the CNS innate immune response and producer/metabolizer of β-amyloid, have been implicated. We hypothesized that Chlamydia pneumoniae infection of human astrocytes alters the expression of the amyloid precursor protein (APP)-processing secretases, ADAM10, BACE1, and PSEN1, to promote β-amyloid formation. Utilizing immunofluorescent microscopy, molecular, and biochemical approaches, these studies explore the role of an intracellular respiratory pathogen, Chlamydia pneumoniae, as an environmental trigger for AD pathology. Human astrocytoma cells in vitro were infected with Chlamydia pneumoniae over the course of 6-72 h. The gene and protein expression, as well as the enzymatic activity of non-amyloidogenic (ADAM10), and pro-amyloidogenic (BACE1 and PSEN1) secretases were qualitatively and quantitatively assessed. In addition, the formation of toxic amyloid products as an outcome of pro-amyloidogenic APP processing was evaluated through various modalities.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Chlamydia pneumoniae infection of human astrocytoma cells promoted the transcriptional upregulation of numerous genes implicated in host neuroinflammation, lipid homeostasis, microtubule function, and APP processing. Relative to that of uninfected astrocytes, BACE1 and PSEN1 protein levels were enhanced by nearly twofold at 48-72 h post-Chlamydia pneumoniae infection. The processing of APP in Chlamydia pneumoniae-infected astrocytes favors the pro-amyloidogenic pathway, as demonstrated by an increase in enzymatic activity of BACE1, while that of ADAM10 was decreased. Fluorescence intensity of β-amyloid and ELISA-quantified levels of soluble-APP by products revealed temporally similar increases, confirming a BACE1/PSEN1-mediated processing of APP.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that Chlamydia pneumoniae infection of human astrocytes promotes the pro-amyloidogenic pathway of APP processing through the upregulation of expression and activity of β-secretase, upregulated expression of γ-secretase, and decreased activity of α-secretase. These effects of astrocyte infection provide evidence for a direct link between Chlamydia pneumoniae and AD pathology.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Al-Atrache</LastName>
                    <ForeName>Zein</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bio-Medical Sciences, Center for Chronic Disorders of Aging, Philadelphia College of Osteopathic Medicine, 4170 City Avenue, Philadelphia, PA, 19131, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lopez</LastName>
                    <ForeName>Danielle B</ForeName>
                    <Initials>DB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bio-Medical Sciences, Center for Chronic Disorders of Aging, Philadelphia College of Osteopathic Medicine, 4170 City Avenue, Philadelphia, PA, 19131, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hingley</LastName>
                    <ForeName>Susan T</ForeName>
                    <Initials>ST</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bio-Medical Sciences, Center for Chronic Disorders of Aging, Philadelphia College of Osteopathic Medicine, 4170 City Avenue, Philadelphia, PA, 19131, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Appelt</LastName>
                    <ForeName>Denah M</ForeName>
                    <Initials>DM</Initials>
                    <Identifier Source="ORCID">0000-0002-0720-4722</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Bio-Medical Sciences, Center for Chronic Disorders of Aging, Philadelphia College of Osteopathic Medicine, 4170 City Avenue, Philadelphia, PA, 19131, USA. DenahA@pcom.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Neurosci</MedlineTA>
            <NlmUniqueID>100966986</NlmUniqueID>
            <ISSNLinking>1471-2202</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.-</RegistryNumber>
                <NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.23.-</RegistryNumber>
                <NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.23.46</RegistryNumber>
                <NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.81</RegistryNumber>
                <NameOfSubstance UI="D000072197">ADAM10 Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.24.81</RegistryNumber>
                <NameOfSubstance UI="C491236">ADAM10 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000072197" MajorTopicYN="N">ADAM10 Protein</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023521" MajorTopicYN="N">Chlamydophila Infections</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016993" MajorTopicYN="Y">Chlamydophila pneumoniae</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
                <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Alzheimer disease</Keyword>
            <Keyword MajorTopicYN="Y">Amyloid</Keyword>
            <Keyword MajorTopicYN="Y">Astrocytes</Keyword>
            <Keyword MajorTopicYN="Y">BACE1</Keyword>
            <Keyword MajorTopicYN="Y">Chlamydia pneumoniae</Keyword>
            <Keyword MajorTopicYN="Y">Neurodegeneration</Keyword>
            <Keyword MajorTopicYN="Y">Neuroinflammation</Keyword>
            <Keyword MajorTopicYN="Y">Pathogens</Keyword>
            <Keyword MajorTopicYN="Y">Secretase</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30786875</ArticleId>
            <ArticleId IdType="doi">10.1186/s12868-019-0489-5</ArticleId>
            <ArticleId IdType="pii">10.1186/s12868-019-0489-5</ArticleId>
            <ArticleId IdType="pmc">PMC6383264</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
        <PMID Version="1">30747419</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0065-2598</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>1118</Volume>
                    <PubDate>
                        <MedlineDate>2019</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Advances in experimental medicine and biology</Title>
                <ISOAbbreviation>Adv. Exp. Med. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms.</ArticleTitle>
            <Pagination>
                <MedlinePgn>83-116</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-030-05542-4_5</ELocationID>
            <Abstract>
                <AbstractText>The accumulation of aggregated amyloid β (Aβ) peptides in the brain is deeply involved in Alzheimer disease (AD) pathogenesis. Mutations in APP and presenilins play major roles in Aβ pathology in rare autosomal-dominant forms of AD, whereas pathomechanisms of sporadic AD, accounting for the majority of cases, remain unknown. In this chapter, we review current knowledge on genetic risk factors of AD, clarified by recent advances in genome analysis technology. Interestingly, TREM2 and many genes associated with disease risk are predominantly expressed in microglia, suggesting that these risk factors are involved in pathogenicity through common mechanisms involving microglia. Therefore, we focus on factors closely associated with microglia and discuss their possible roles in pathomechanisms of AD. Furthermore, we review current views on the pathological roles of microglia and emphasize the importance of microglial changes in response to Aβ deposition and mechanisms underlying the phenotypic changes. Importantly, functional outcomes of microglial activation can be both protective and deleterious to neurons. We further describe the involvement of microglia in tau pathology and the activation of other glial cells. Through these topics, we shed light on microglia as a promising target for drug development for AD and other neurological disorders.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Takatori</LastName>
                    <ForeName>Sho</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Wenbo</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Iguchi</LastName>
                    <ForeName>Akihiro</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomita</LastName>
                    <ForeName>Taisuke</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. taisuke@mol.f.u-tokyo.ac.jp.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Adv Exp Med Biol</MedlineTA>
            <NlmUniqueID>0121103</NlmUniqueID>
            <ISSNLinking>0065-2598</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alzheimer disease (AD)</Keyword>
            <Keyword MajorTopicYN="N">Amyloid hypothesis</Keyword>
            <Keyword MajorTopicYN="N">Amyloid β (Aβ)</Keyword>
            <Keyword MajorTopicYN="N">Genetic risk factor</Keyword>
            <Keyword MajorTopicYN="N">Genome-wide association study (GWAS)</Keyword>
            <Keyword MajorTopicYN="N">Microglia</Keyword>
            <Keyword MajorTopicYN="N">Neurodegenerative disease</Keyword>
            <Keyword MajorTopicYN="N">Neuroinflammation</Keyword>
            <Keyword MajorTopicYN="N">Rare variant</Keyword>
            <Keyword MajorTopicYN="N">Single nucleotide polymorphism (SNP)</Keyword>
            <Keyword MajorTopicYN="N">Sporadic AD</Keyword>
            <Keyword MajorTopicYN="N">Tau</Keyword>
            <Keyword MajorTopicYN="N">Triggering receptor expressed on myeloid cells 2 (TREM2)</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30747419</ArticleId>
            <ArticleId IdType="doi">10.1007/978-3-030-05542-4_5</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30745444</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>11</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1526-632X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>92</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>02</Month>
                        <Day>12</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neurology</Title>
                <ISOAbbreviation>Neurology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>329-337</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000006926</ELocationID>
            <Abstract>
                <AbstractText>The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid into plaques and hyperphosphorylated tau into tangles. Implicit in this clinicopathologic-based nosology is the assumption that pathologic protein aggregation at autopsy reflects pathogenesis at disease onset. While these aggregates may in exceptional cases be on a causal pathway in humans (e.g., aggregated α-synuclein in <i>SNCA</i> gene multiplication or aggregated β-amyloid in <i>APP</i> mutations), their near universality at postmortem in sporadic PD and AD suggests they may alternatively represent common outcomes from upstream mechanisms or compensatory responses to cellular stress in order to delay cell death. These 3 conceptual frameworks of protein aggregation (pathogenic, epiphenomenon, protective) are difficult to resolve because of the inability to probe brain tissue in real time. Whereas animal models, in which neither PD nor AD occur in natural states, consistently support a pathogenic role of protein aggregation, indirect evidence from human studies does not. We hypothesize that (1) current biomarkers of protein aggregates may be relevant to common pathology but not to subgroup pathogenesis and (2) disease-modifying treatments targeting oligomers or fibrils might be futile or deleterious because these proteins are epiphenomena or protective in the human brain under molecular stress. Future precision medicine efforts for molecular targeting of neurodegenerative diseases may require analyses not anchored on current clinicopathologic criteria but instead on biological signals generated from large deeply phenotyped aging populations or from smaller but well-defined genetic-molecular cohorts.</AbstractText>
                <CopyrightInformation>© 2019 American Academy of Neurology.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Espay</LastName>
                    <ForeName>Alberto J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio. alberto.espay@uc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vizcarra</LastName>
                    <ForeName>Joaquin A</ForeName>
                    <Initials>JA</Initials>
                    <Identifier Source="ORCID">0000-0003-0306-4774</Identifier>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marsili</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lang</LastName>
                    <ForeName>Anthony E</ForeName>
                    <Initials>AE</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simon</LastName>
                    <ForeName>David K</ForeName>
                    <Initials>DK</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Merola</LastName>
                    <ForeName>Aristide</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Josephs</LastName>
                    <ForeName>Keith A</ForeName>
                    <Initials>KA</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fasano</LastName>
                    <ForeName>Alfonso</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morgante</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Savica</LastName>
                    <ForeName>Rodolfo</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greenamyre</LastName>
                    <ForeName>J Timothy</ForeName>
                    <Initials>JT</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cambi</LastName>
                    <ForeName>Franca</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yamasaki</LastName>
                    <ForeName>Tritia R</ForeName>
                    <Initials>TR</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tanner</LastName>
                    <ForeName>Caroline M</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gan-Or</LastName>
                    <ForeName>Ziv</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Litvan</LastName>
                    <ForeName>Irene</ForeName>
                    <Initials>I</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mata</LastName>
                    <ForeName>Ignacio F</ForeName>
                    <Initials>IF</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zabetian</LastName>
                    <ForeName>Cyrus P</ForeName>
                    <Initials>CP</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brundin</LastName>
                    <ForeName>Patrik</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fernandez</LastName>
                    <ForeName>Hubert H</ForeName>
                    <Initials>HH</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Standaert</LastName>
                    <ForeName>David G</ForeName>
                    <Initials>DG</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kauffman</LastName>
                    <ForeName>Marcelo A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwarzschild</LastName>
                    <ForeName>Michael A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sardi</LastName>
                    <ForeName>S Pablo</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sherer</LastName>
                    <ForeName>Todd</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Perry</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leverenz</LastName>
                    <ForeName>James B</ForeName>
                    <Initials>JB</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the UC Gardner Neuroscience Institute and Gardner Family Center for Parkinson's Disease and Movement Disorders (A.J.E., J.A.V., L.M., A.M.), Department of Neurology, University of Cincinnati, OH; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic (A.E.L., A.F.), Toronto Western Hospital, University of Toronto; Krembil Research Institute (A.E.L., A.F.), Toronto, Canada; Parkinson's Disease and Movement Disorders Center (D.K.S.), Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; College of Medicine (K.A.J.), Mayo Clinic, Rochester, MN; Institute of Molecular and Clinical Sciences (F.M.), St George's University of London, UK; Division of Movement Disorders (R.S.), Department of Neurology and Department of Health Science Research, Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology and the Pittsburgh Institute for Neurodegenerative Diseases (J.T.G., F.C.), University of Pittsburgh, PA; Department of Neurology (T.R.Y.), University of Kentucky, Lexington; Parkinson's Disease Research, Education and Clinical Center (C.M.T.), Neurology, San Francisco Veterans Affairs Medical Center; Department of Neurology (C.M.T.), University of California-San Francisco; Department of Neurology &amp; Neurosurgery, Montreal Neurological Institute, and Department of Human Genetics (Z.G.-O.), McGill University, Canada; Parkinson &amp; Other Movement Disorders Center UC San Diego (I.L.), Department of Neurosciences, Altman Clinical Translational Research Institute, La Jolla, CA; VA Puget Sound Health Care System and Department of Neurology (I.F.M., CP.Z.), University of Washington, Seattle; Department of Neurology (I.F.M.), University of Washington School of Medicine, Seattle; Center for Neurodegenerative Science (P.B.), Van Andel Research Institute, Grand Rapids, MI; Center for Neurological Restoration (H.H.F.) and Lou Ruvo Center for Brain Health, Neurological Institute (J.B.L.), Cleveland Clinic, OH; Department of Neurology (D.G.S.), University of Alabama at Birmingham; Consultorio y Laboratorio de Neurogenética (M.A.K.), Centro Universitario de Neurología &quot;José María Ramos Mejía&quot; y División Neurología, Hospital JM Ramos Mejía, Facultad de Medicina, UBA; Programa de Medicina de Precision y Genomica Clinica (M.A.K.), Instituto de Investigaciones en Medicina Traslacional, Facultad de Ciencias Biomédicas, Universidad Austral-CONICET, Buenos Aires, Argentina; Department of Neurology (M.A.S.), Massachusetts General Hospital, Boston; Division of Neuroscience (S.P.S.), Sanofi-Genzyme, Framingham, MA; Michael J. Fox Foundation for Parkinson's Research (T.S.), New York, NY; and College of Sciences (G.P.), University of Texas at San Antonio.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>KL2 TR001996</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Neurology</MedlineTA>
            <NlmUniqueID>0401060</NlmUniqueID>
            <ISSNLinking>0028-3878</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015984" MajorTopicYN="N">Causality</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>07</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2020</Year>
                <Month>02</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>11</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30745444</ArticleId>
            <ArticleId IdType="pii">92/7/329</ArticleId>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006926</ArticleId>
            <ArticleId IdType="pmc">PMC6382364</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30725250</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>05</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-6830</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>39</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cellular and molecular neurobiology</Title>
                <ISOAbbreviation>Cell. Mol. Neurobiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Artemisia amygdalina Upregulates Nrf2 and Protects Neurons Against Oxidative Stress in Alzheimer Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>387-399</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10571-019-00656-w</ELocationID>
            <Abstract>
                <AbstractText>Alzheimer disease is a complex neurodegenerative disorder. It is the common form of dementia in elderly people. The etiology of this disease is multifactorial, pathologically it is accompanied with accumulation of amyloid beta and neurofibrillary tangles. Accumulation of amyloid beta and mitochondrial dysfunction leads to oxidative stress. In this study, neuroprotective effect of Artemisiaamygdalina against H<sub>2</sub>O<sub>2</sub>-induced death was studied in differentiated N2a and SH-SY5Ycells. Cells were treated with H<sub>2</sub>O<sub>2</sub> to induce toxicity which was attenuated by Artemisia amygdalina. The nuclear factor erythroid 2-related factor 2 (Nrf2) is an emerging regulator of cellular resistance to oxidants. It controls the basal and induced expression of antioxidant response element-dependent genes. Further, we demonstrated that Artemisia amygdalina protects neurons through upregulation of Nrf2 pathway. Moreover, reactive oxygen species and mitochondrial membrane potential loss formed by H<sub>2</sub>O<sub>2</sub> was attenuated by Artemisia amygdalina. Thus, Artemisia amygdalina may have the possibility to be a therapeutic agent for Alzheimer disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sajjad</LastName>
                    <ForeName>Nasreena</ForeName>
                    <Initials>N</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4738-3892</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, University of Kashmir, Srinagar, 190006, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wani</LastName>
                    <ForeName>Abubakar</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>PK-PD- Toxicology and Formulation, CSIR- Indian Institute of Integrative Medicine, Jammu, 180001, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharma</LastName>
                    <ForeName>Ankita</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>PK-PD- Toxicology and Formulation, CSIR- Indian Institute of Integrative Medicine, Jammu, 180001, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ali</LastName>
                    <ForeName>Rohaya</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, University of Kashmir, Srinagar, 190006, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hassan</LastName>
                    <ForeName>Sumaya</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, University of Kashmir, Srinagar, 190006, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamid</LastName>
                    <ForeName>Rabia</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, University of Kashmir, Srinagar, 190006, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Habib</LastName>
                    <ForeName>Huma</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Islamia College of Science and Commerce, Srinagar, 190002, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ganai</LastName>
                    <ForeName>Bashir Ahmad</ForeName>
                    <Initials>BA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre of Research for Development, University of Kashmir, Srinagar, 190006, India. bbcganai@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>F1-17.1/2016-2017/MANF-2015-17-JAM 59027/(SA-111)</GrantID>
                    <Agency>University Grants Commission</Agency>
                    <Country/>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Cell Mol Neurobiol</MedlineTA>
            <NlmUniqueID>8200709</NlmUniqueID>
            <ISSNLinking>0272-4340</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001713">Biphenyl Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010636">Phenols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010851">Picrates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>11062-77-4</RegistryNumber>
                <NameOfSubstance UI="D013481">Superoxides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3352-57-6</RegistryNumber>
                <NameOfSubstance UI="D017665">Hydroxyl Radical</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BBX060AN9V</RegistryNumber>
                <NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>DFD3H4VGDH</RegistryNumber>
                <NameOfSubstance UI="C004931">1,1-diphenyl-2-picrylhydrazyl</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.18</RegistryNumber>
                <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019306" MajorTopicYN="N">Artemisia</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001713" MajorTopicYN="N">Biphenyl Compounds</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048430" MajorTopicYN="N">Cell Shape</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
                <QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017665" MajorTopicYN="N">Hydroxyl Radical</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010084" MajorTopicYN="N">Oxidation-Reduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010636" MajorTopicYN="N">Phenols</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010851" MajorTopicYN="N">Picrates</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013481" MajorTopicYN="N">Superoxides</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015854" MajorTopicYN="Y">Up-Regulation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Antioxidant</Keyword>
            <Keyword MajorTopicYN="N">Artemisia amygdalina</Keyword>
            <Keyword MajorTopicYN="N">Neuroprotection</Keyword>
            <Keyword MajorTopicYN="N">Nrf2</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>5</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30725250</ArticleId>
            <ArticleId IdType="doi">10.1007/s10571-019-00656-w</ArticleId>
            <ArticleId IdType="pii">10.1007/s10571-019-00656-w</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30707667</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>10</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">2332-8363</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Issue>121</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>12</Month>
                    </PubDate>
                </JournalIssue>
                <Title>National health statistics reports</Title>
                <ISOAbbreviation>Natl Health Stat Report</ISOAbbreviation>
            </Journal>
            <ArticleTitle>National Hospital Care Survey Demonstration Projects: Characteristics of Inpatient and Emergency Department Encounters Among Patients With Any Listed Diagnosis of Alzheimer Disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Objective-This report demonstrates the use of National Hospital Care Survey (NHCS) data using Alzheimer disease (AD) as an outcome. Inpatient discharges and emergency room encounters among patients with AD are described to demonstrate the use of NHCS. The capability of NHCS to link across hospital settings and to the National Death Index (NDI) is highlighted. The data are unweighted and are not nationally representative. Methods-This study analyzed inpatient (IP) and emergency department (ED) data from the 83 nonchildren's hospitals in the 2014 NHCS, out of a sample of 581 hospitals that provided Uniform Bill (UB)-04 administrative claims data for both the IP and ED settings. Encounters with any listed diagnosis of AD were identified using an International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code. Individual patients who had any encounter during calendar year 2014 were linked across different hospital-based settings during the same year and with NDI to identify deaths in 2014 or 2015. Results-Analyses are presented on IP and ED encounters with any listed diagnosis of AD to highlight the analytical capabilities of NHCS not available in previous surveys. New data elements not available in the National Hospital Discharge Survey (NHCS' predecessor survey) are analyzed, including intensive care use, and diagnostic and therapeutic services received. Linkage across hospital settings (IP and ED) allows for differentiation of patients who were admitted directly as inpatients from those who were admitted as inpatients from the ED, and allows for identification of patients with only an ED encounter. Linkage to NDI allows for analyses of the underlying cause of death for those deaths occurring in 2014 and 2015. Although these data are not nationally representative, NHCS provides unique analytical opportunities to examine health care utilization among patients with AD across settings.</AbstractText>
                <CopyrightInformation>All material appearing in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bercovitz</LastName>
                    <ForeName>Anita</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jamoom</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lau</LastName>
                    <ForeName>Denys T</ForeName>
                    <Initials>DT</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Natl Health Stat Report</MedlineTA>
            <NlmUniqueID>101479519</NlmUniqueID>
            <ISSNLinking>2164-8344</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>H</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004636" MajorTopicYN="N">Emergency Service, Hospital</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019538" MajorTopicYN="Y">Health Care Surveys</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014600" MajorTopicYN="Y">Utilization Review</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>2</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>28</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30707667</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30690248</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-264X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>166</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Mar</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of pharmaceutical and biomedical analysis</Title>
                <ISOAbbreviation>J Pharm Biomed Anal</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A metabolomic study based on accurate mass and isotopic fine structures by dual mode combined-FT-ICR-MS to explore the effects of Rhodiola crenulata extract on Alzheimer disease in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>347-356</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0731-7085(18)31818-1</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpba.2019.01.021</ELocationID>
            <Abstract>
                <AbstractText>A metabolomic strategy based on accurate mass and isotopic fine structures (IFSs) by dual mode combined-Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS) was established to explore the effects of Rhodiola crenulata extract (RCE) on Alzheimer disease (AD) in rats. Experimental AD model was induced in rats by bilateral hippocampal injection of Aβ<sub>1-42</sub>, and Morris water maze task (MWM) was used to evaluate the effects of RCE on AD. Subsequently, the metabolomic study was performed using HPLC-FT-ICR-MS, fraction collector and direct infusion (DI)-FT-ICR-MS to screen and identify the potential biomarkers. A total of 20 metabolites contributing to AD progress were identified, and 17 metabolites of them were restored to the control-like levels after RCE treatment (daily dose: 2.24 g/kg). The metabolic pathway analysis revealed that the disturbed pathways including tryptophan metabolism, sphingolipid metabolism and glycerophospholipid metabolism in AD model rats were regulated after high dose RCE application. It is the first time that the dual mode combined-FT-ICR-MS based metabolomic strategy was applied to biochemically profile the serum metabolic pathways of AD rats affected by RCE. These outcomes provide reliable evidence to illuminate the biochemical mechanisms of AD and facilitate investigation of the therapeutic benefits of RCE in AD treatment. Notably, it indicated that the developed method based on accurate mass and IFSs has sufficient performance for identification of biomarkers in metabolomic studies.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaoxue</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiang</LastName>
                    <ForeName>Xiwei</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Medical Devices, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Xue</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Yangyang</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Lianqun</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Ministry of Education for TCM Viscera-State Theory and Applications, Liaoning University of Traditional Chinese Medicine, 79 Chongshan Eastern Road, Huanggu District, Shenyang, 110032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Fen</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Key Laboratory of Ministry of Education for TCM Viscera-State Theory and Applications, Liaoning University of Traditional Chinese Medicine, 79 Chongshan Eastern Road, Huanggu District, Shenyang, 110032, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yin</LastName>
                    <ForeName>Ran</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Han</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China. Electronic address: hanfei_spu@163.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Pharm Biomed Anal</MedlineTA>
            <NlmUniqueID>8309336</NlmUniqueID>
            <ISSNLinking>0731-7085</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005583" MajorTopicYN="N">Fourier Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053858" MajorTopicYN="N">Metabolic Networks and Pathways</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055432" MajorTopicYN="N">Metabolomics</DescriptorName>
                <QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D029771" MajorTopicYN="N">Rhodiola</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Accurate mass</Keyword>
            <Keyword MajorTopicYN="N">FT-ICR-MS</Keyword>
            <Keyword MajorTopicYN="N">Isotopic fine structures</Keyword>
            <Keyword MajorTopicYN="N">Metabolomic study</Keyword>
            <Keyword MajorTopicYN="N">Rhodiola crenulata</Keyword>
            <Keyword MajorTopicYN="N">tRaditional Chinese medicines</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>08</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30690248</ArticleId>
            <ArticleId IdType="pii">S0731-7085(18)31818-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.jpba.2019.01.021</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30677568</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>04</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-928X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>78</Volume>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Computational biology and chemistry</Title>
                <ISOAbbreviation>Comput Biol Chem</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Structural bioinformatics-based identification of putative plant based lead compounds for Alzheimer Disease Therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>359-366</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1476-9271(18)30906-X</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.compbiolchem.2018.12.012</ELocationID>
            <Abstract>
                <AbstractText>Plant based lead compounds have been historically incredible as a source of therapeutic agents for various complex disorders including Alzheimer's disease (AD). AD is one of the leading neurodegenerative disorder in which the underlying risk factors remain largely unclear and presently, there is no disease modifying treatment available. Despite its potential, to date only few compounds have entered for clinical trials. Herein, we described the identification of plant based lead compounds for treatment of AD through an integrative approach of pharmacokinetics and structure bioinformatics approach. In particular we performed screening of lead compounds from 3 traditional medicinal plants namely Withania somnifera, Bacopa monnieri and Morus alba, which are known to have potential for treatment of neurodegenerative disease. We retrieved a total of 210 plant based compounds of which 21 compounds were screened based on their pharmacokinetic properties. Further, Docking study against 7 known AD associated targets were carried out to identify the binding sites and direct interacting residues. In addition we investigate the stable and reliable binding mechanism of top such plant compounds against 3 targets through molecular docking followed by Molecular Dynamic(MD) simulation. The results obtained in the study revealed that 3 drug compounds namely Morusin (MRSN), Withanone (WTHN) and 27-Hydroxywithanolide B (HWTHN) were identified as putative lead compounds against mono amine oxidase (MAOB), Beta-secretase 1(BACE1) and phosphodiesterase 4D.</AbstractText>
                <CopyrightInformation>Copyright © 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Borah</LastName>
                    <ForeName>Kasmika</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics Infrastructure Facility Center, Biological Sciences &amp; Technology Division, CSIR-North-East Institute of Science and Technology, Jorhat, Assam, 785006, India. Electronic address: bio.sillayumnam@gmail.com.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharma</LastName>
                    <ForeName>Sanchita</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics Infrastructure Facility Center, Biological Sciences &amp; Technology Division, CSIR-North-East Institute of Science and Technology, Jorhat, Assam, 785006, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silla</LastName>
                    <ForeName>Yumnam</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bioinformatics Infrastructure Facility Center, Biological Sciences &amp; Technology Division, CSIR-North-East Institute of Science and Technology, Jorhat, Assam, 785006, India. Electronic address: ysilla@neist.res.in.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>01</Month>
                <Day>08</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Comput Biol Chem</MedlineTA>
            <NlmUniqueID>101157394</NlmUniqueID>
            <ISSNLinking>1476-9271</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C560597">6,7-epoxy-5,17-dihydroxy-1-oxowitha-2,24-dienolide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005419">Flavonoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014315">Triterpenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>62596-29-6</RegistryNumber>
                <NameOfSubstance UI="C057451">morusin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034681" MajorTopicYN="N">Bacopa</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005419" MajorTopicYN="N">Flavonoids</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D031625" MajorTopicYN="N">Morus</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014315" MajorTopicYN="N">Triterpenes</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D032341" MajorTopicYN="N">Withania</DescriptorName>
                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Binding sites</Keyword>
            <Keyword MajorTopicYN="N">Docking</Keyword>
            <Keyword MajorTopicYN="N">Molecular dynamic simulation</Keyword>
            <Keyword MajorTopicYN="N">Pharmacokinetics</Keyword>
            <Keyword MajorTopicYN="N">Plant-base lead compounds</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2018</Year>
                <Month>11</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2018</Year>
                <Month>12</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>4</Month>
                <Day>4</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30677568</ArticleId>
            <ArticleId IdType="pii">S1476-9271(18)30906-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.compbiolchem.2018.12.012</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30646251</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2574-3805</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>10</Month>
                        <Day>05</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA network open</Title>
                <ISOAbbreviation>JAMA Netw Open</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e183597</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2018.3597</ELocationID>
            <Abstract>
                <AbstractText Label="Importance">The association between peripheral inflammatory biomarkers and Alzheimer disease (AD) is not consistent in the literature. It is possible that chronic inflammation, rather than 1 episode of inflammation, interacts with genetic vulnerability to increase the risk for AD.</AbstractText>
                <AbstractText Label="Objective">To study the interaction between the apolipoprotein E (ApoE) genotype and chronic low-grade inflammation and its association with the incidence of AD.</AbstractText>
                <AbstractText Label="Design, Setting, and Participants">In this cohort study, data from 2656 members of the Framingham Heart Study offspring cohort (Generation 2; August 13, 1971-November 27, 2017) were evaluated, including longitudinal measures of serum C-reactive protein (CRP), diagnoses of incident dementia including AD, and brain volume. Chronic low-grade inflammation was defined as having CRP at a high cutoff level at a minimum of 2 time points. Statistical analysis was performed from December 1, 1979, to December 31, 2015.</AbstractText>
                <AbstractText Label="Main Outcomes and Measures">Development of AD and brain volumes.</AbstractText>
                <AbstractText Label="Results">Of the 3130 eligible participants, 2656 (84.9%; 1227 men and 1429 women; mean [SD] age at last CRP measurement, 61.6 [9.5] years) with both ApoE status and longitudinal CRP measurements were included in this study analysis. Median (interquartile range) CRP levels increased with mean (SD) age (43.3 [9.6] years, 0.95 mg/L [0.40-2.35 mg/L] vs 59.1 [9.6] years, 2.04 mg/L [0.93-4.75 mg/L] vs 61.6 [9.5] years, 2.21 mg/L [1.05-5.12 mg/L]; P &lt; .001), but less so among those with ApoE4 alleles, followed by ApoE3 then ApoE2 genotypes. During the 17 years of follow-up, 194 individuals (7.3%) developed dementia, 152 (78.4%) of whom had AD. ApoE4 coupled with chronic low-grade inflammation, defined as a CRP level of 8 mg/L or higher, was associated with an increased risk of AD, especially in the absence of cardiovascular diseases (hazard ratio, 6.63; 95% CI, 1.80-24.50; P = .005), as well as an increased risk of earlier disease onset compared with ApoE4 carriers without chronic inflammation (hazard ratio, 3.52; 95% CI, 1.27-9.75; P = .009). This phenomenon was not observed among ApoE3 and ApoE2 carriers with chronic low-grade inflammation. Finally, a subset of 1761 individuals (66.3%) underwent brain magnetic resonance imaging, and the interaction between ApoE4 and chronic low-grade inflammation was associated with brain atrophy in the temporal lobe (β = -0.88, SE = 0.22; P &lt; .001) and hippocampus (β = -0.04, SE = 0.01; P = .005), after adjusting for confounders.</AbstractText>
                <AbstractText Label="Conclusions and Relevance">In this study, peripheral chronic low-grade inflammation in participants with ApoE4 was associated with shortened latency for onset of AD. Rigorously treating chronic systemic inflammation based on genetic risk could be effective for the prevention and intervention of AD.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tao</LastName>
                    <ForeName>Qiushan</ForeName>
                    <Initials>Q</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ang</LastName>
                    <ForeName>Ting Fang Alvin</ForeName>
                    <Initials>TFA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>DeCarli</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Alzheimer's Disease Center, University of California Davis Medical Center, Sacramento.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Auerbach</LastName>
                    <ForeName>Sanford H</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Devine</LastName>
                    <ForeName>Sheral</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Framingham Heart Study, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stein</LastName>
                    <ForeName>Thor D</ForeName>
                    <Initials>TD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Veterans Affairs Boston Healthcare System, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Alzheimer's Disease Center, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Xiaoling</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Massaro</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Framingham Heart Study, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Au</LastName>
                    <ForeName>Rhoda</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Framingham Heart Study, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Alzheimer's Disease Center, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qiu</LastName>
                    <ForeName>Wei Qiao</ForeName>
                    <Initials>WQ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Alzheimer's Disease Center, Boston University School of Medicine, Boston, Massachusetts.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>K24 AG050842</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 AG010129</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>N01HC25195</GrantID>
                    <Acronym>HL</Acronym>
                    <Agency>NHLBI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>10</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA Netw Open</MedlineTA>
            <NlmUniqueID>101729235</NlmUniqueID>
            <ISSNLinking>2574-3805</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9007-41-4</RegistryNumber>
                <NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName>
                <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30646251</ArticleId>
            <ArticleId IdType="pii">2707427</ArticleId>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2018.3597</ArticleId>
            <ArticleId IdType="pmc">PMC6324596</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">30646141</PMID>
        <DateCompleted>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>09</Month>
            <Day>25</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2574-3805</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>09</Month>
                        <Day>07</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA network open</Title>
                <ISOAbbreviation>JAMA Netw Open</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adolescent Cognitive Aptitudes and Later-in-Life Alzheimer Disease and Related Disorders.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e181726</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2018.1726</ELocationID>
            <Abstract>
                <AbstractText Label="Importance">Low early-life cognitive ability is a potential early marker of dementia risk in later life. Previous studies use only global measures of general intelligence and/or study this relationship in gender-specific samples. The contribution of early-life performance on specific cognitive abilities, such as language, reasoning, and visualization aptitudes, to indicating future dementia risk is unknown.</AbstractText>
                <AbstractText Label="Objectives">To investigate the association between adolescent cognitive ability and Medicare-recorded Alzheimer disease and related disorders (ADRD) using both general and specific measures of cognitive ability and to explore these associations separately in men and women.</AbstractText>
                <AbstractText Label="Design, Setting, and Participants">Population-based cohort study from the Project Talent-Medicare linked data set, a linkage of adolescent sociobehavioral data collected from high school students in 1960 to participants' 2012 to 2013 Medicare Claims and expenditures data. The association between adolescent cognitive ability and risk of ADRD in later life was assessed in a diverse sample of 43 014 men and 42 749 women aged 66 to 73 years using a series of logistic regressions stratified by sex, accounting for demographic characteristics, adolescent socioeconomic status, and regional effects. Data analysis was conducted from November 2017 to March 2018.</AbstractText>
                <AbstractText Label="Main Outcomes and Measures">Presence of Medicare-reported ADRD.</AbstractText>
                <AbstractText Label="Results">Overall, 1239 men (2.9%) and 1416 women (3.3%) developed ADRD. Lower mechanical reasoning was associated with increased odds of ADRD in men (odds ratio, 1.17; 95% CI, 1.05-1.29), and lower memory for words in adolescence was associated with increased odds of ADRD in women (odds ratio, 1.16; 95% CI, 1.05-1.28). Lower performance on several other language, reasoning, visualization, and mathematic aptitudes in adolescence showed prominent, but weaker, associations with odds of ADRD.</AbstractText>
                <AbstractText Label="Conclusions and Relevance">This work contributes to the understanding of early-life origins of ADRD risk. The results suggest specific measures of cognitive ability may contribute to very early identification of at-risk subgroups who may benefit from prevention or intervention efforts.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Alison R</ForeName>
                    <Initials>AR</Initials>
                    <AffiliationInfo>
                        <Affiliation>American Institutes for Research, Washington, DC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strombotne</LastName>
                    <ForeName>Kiersten L</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>American Institutes for Research, Washington, DC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horner</LastName>
                    <ForeName>Elizabeth Mokyr</ForeName>
                    <Initials>EM</Initials>
                    <AffiliationInfo>
                        <Affiliation>American Institutes for Research, Washington, DC.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lapham</LastName>
                    <ForeName>Susan J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>American Institutes for Research, Washington, DC.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>09</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>JAMA Netw Open</MedlineTA>
            <NlmUniqueID>101729235</NlmUniqueID>
            <ISSNLinking>2574-3805</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>JAMA Netw Open. 2018 Sep 7;1(5):e181724</RefSource>
                <PMID Version="1">30646136</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName>
                <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
                <QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004521" MajorTopicYN="N">Educational Measurement</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName>
                <QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>1</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>9</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">30646141</ArticleId>
            <ArticleId IdType="pii">2701735</ArticleId>
            <ArticleId IdType="doi">10.1001/jamanetworkopen.2018.1726</ArticleId>
            <ArticleId IdType="pmc">PMC6324501</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>



</PubmedArticleSet>